CA2262014C - Adipogenic differentiation of human mesenchymal stem cells - Google Patents
Adipogenic differentiation of human mesenchymal stem cells Download PDFInfo
- Publication number
- CA2262014C CA2262014C CA2262014A CA2262014A CA2262014C CA 2262014 C CA2262014 C CA 2262014C CA 2262014 A CA2262014 A CA 2262014A CA 2262014 A CA2262014 A CA 2262014A CA 2262014 C CA2262014 C CA 2262014C
- Authority
- CA
- Canada
- Prior art keywords
- cells
- camp
- differentiate
- mesenchymal stem
- adipocytes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0653—Adipocytes; Adipose tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/39—Steroid hormones
Abstract
A composition which comprises human mesenchymal stem cells which have the potential to differentiate into cells of more than one connective tissue type and a composition which induces cells from the mesenchymal stem cell population to differentiate into the adipogenic lineage, and a process for inducing such differentiation. The composition for inducing such differentiation comprises a glucocorticoid and a compound which stimulates cAMP production or inhibits cAMP degradation (such as a phosphodiesterase inhibitor). The process can further include isolating the adipocytes from remaining hMSCs.
Description
ADIPOGENIC DIFFERENTIATION
OF HUMAN MESENCHYMAL STEM CELLS
This application is a continuation-in-part of U.S. Patent No. 5,827,740 issued Oct. 27, 1998.
This invention relates to adipocytes and more particularly to producing adipocytes from human mesenchymal stem cells.
Adipose tissue provides an energy storage reserve for the body in the form of triglycerides and this tissue can release free fatty acids when caloric intake falls below metabolic needs. In response to increased dietary intake, the body will normally automatically increase energy expenditure through activity to maintain an energy balance. Energy can also be released as heat. Adipose tissue is intimately involved in the maintenance of body temperature through brown adipose tissue and energy storage through white adipose tissue. There are normal energy regulation pathways that balance dietary intake with metabolic activity largely mediated through the hypothalamus. It is now also apparent that the adipocyte plays an active role in this process and likely produces molecules that serve to feed back and effect regulation of triglyceride metabolism.
The two types of adipose tissue, brown and white, carry out very different roles in the body. White adipose is designed to store excess caloric intake while brown adipose tissue uses a unique system to syphon off excess calories and use it to generate body heat. The heat is generated in the mitochondria of brown adipose where oxidation of substrate is utilized to create a hydrogen ion gradient that is then collapsed in a regulated fashion generating heat instead of ATP. It has been shown that transgenic animals that lack brown adipose maintain efficient metabolism, are obese and continue to overeat (Lowell et al, Nature. 1993 Dec 23-30; 366 (6457):740-2).
Other rodent studies have also shown a link between obesity, continued overeating and a sensitivity to cold, suggesting a connection to the sympathetic nervous system (Friedman and Leibel, Cell. 1992 Apr 17; 69(2):217-20).
Imbalance in energy metabolism in the body leads to several diseased states, most notably obesity and obesity-induced diabetes and these can be described as dysfunctions of energy storage tissues. A mutation in mice that leads to obesity was identified in 1950 (Ingalls et al., 1950) and the gene was recently identified by positional cloning. The product of the ob gene is a 16,000 mw protein named leptin or OB protein. Leptin is produced only by adipocytes and is a hormone which regulates the hypothalamus. A mutation has been identified in the of mouse that results in premature termination of mRNA translation such that no functional leptin protein is made (Zhang et al. 1994). The role of leptin in regulation of lipid metabolism is an area of intense research.
Recent published investigations include studies of the upstream promoter elements found adjacent to the ob gene which have been shown to bind C/EBP (or CCAAT/enhancer binding protein) (Yeh et al, 1995 and Hwang et al., 1996). Having a model experimental system for in vitro adipogenesis of human cells would provide for discoveries in this area.
-2a-Recently it has been reported that leptin may serve as a hormone that regulates fertility and may be the link between appropriate body weight and reproductive physiology (Chehab et al. 1996). Both underweight and overweight women have difficulty in conceiving and this is likely associated with hormonal imbalance in the body of these individuals. The connection between body weight, fertility and the leptin produced by adipocytes has been suspected and now tested in mice. When obese mice, which normally do not produce offspring without transplanting the ovaries to surrogate females, were injected with leptin, there body weight fell dramatically and they were able to give birth to their own litters (Chehab et al, 1996).
A variety of cell types have been shown to produce lipid containing vesicles under specific culture conditions. For example, mouse 3T3-Ll cells derived from NIH
3T3, an immortalized mouse cell line, can be grown and cultured as a fibroblastic cell.
However, after exposure to dexamethasone and methyl-isobutylxanthine, the cells undergo differentiation which results in the production of intracellular lipid-containing vacuoles (Spiegelman and Green, 1981). Rat marrow stromal cells have been shown to undergo both osteogenic and adipogenic differentiation when cultured with fetal calf serum and dexamethasone, but the predominating cell type varies depending on conditions (Beresford et al., 1992). Specifically, when the steroid analog dexamethasone was present throughout the time course of culture, osteogenesis was favored; but when dexamethasone was present only during secondary culture, the adipogenetic pathway predominated as evidenced by lineage specific markers and cytological observation. Mouse derived CH3 lOT 1 /2 cells are a multipotential cell line that, when treated with 5-azacytidine, undergoes terminal differentiation into adipocytes, myocytes and chondrocytes. The 5-azacytidine causes inhibition of DNA
methylation and thus causes the activation of a few genes responsible for commitment to these lineages (Konieczny and Emerson, 1984).
OF HUMAN MESENCHYMAL STEM CELLS
This application is a continuation-in-part of U.S. Patent No. 5,827,740 issued Oct. 27, 1998.
This invention relates to adipocytes and more particularly to producing adipocytes from human mesenchymal stem cells.
Adipose tissue provides an energy storage reserve for the body in the form of triglycerides and this tissue can release free fatty acids when caloric intake falls below metabolic needs. In response to increased dietary intake, the body will normally automatically increase energy expenditure through activity to maintain an energy balance. Energy can also be released as heat. Adipose tissue is intimately involved in the maintenance of body temperature through brown adipose tissue and energy storage through white adipose tissue. There are normal energy regulation pathways that balance dietary intake with metabolic activity largely mediated through the hypothalamus. It is now also apparent that the adipocyte plays an active role in this process and likely produces molecules that serve to feed back and effect regulation of triglyceride metabolism.
The two types of adipose tissue, brown and white, carry out very different roles in the body. White adipose is designed to store excess caloric intake while brown adipose tissue uses a unique system to syphon off excess calories and use it to generate body heat. The heat is generated in the mitochondria of brown adipose where oxidation of substrate is utilized to create a hydrogen ion gradient that is then collapsed in a regulated fashion generating heat instead of ATP. It has been shown that transgenic animals that lack brown adipose maintain efficient metabolism, are obese and continue to overeat (Lowell et al, Nature. 1993 Dec 23-30; 366 (6457):740-2).
Other rodent studies have also shown a link between obesity, continued overeating and a sensitivity to cold, suggesting a connection to the sympathetic nervous system (Friedman and Leibel, Cell. 1992 Apr 17; 69(2):217-20).
Imbalance in energy metabolism in the body leads to several diseased states, most notably obesity and obesity-induced diabetes and these can be described as dysfunctions of energy storage tissues. A mutation in mice that leads to obesity was identified in 1950 (Ingalls et al., 1950) and the gene was recently identified by positional cloning. The product of the ob gene is a 16,000 mw protein named leptin or OB protein. Leptin is produced only by adipocytes and is a hormone which regulates the hypothalamus. A mutation has been identified in the of mouse that results in premature termination of mRNA translation such that no functional leptin protein is made (Zhang et al. 1994). The role of leptin in regulation of lipid metabolism is an area of intense research.
Recent published investigations include studies of the upstream promoter elements found adjacent to the ob gene which have been shown to bind C/EBP (or CCAAT/enhancer binding protein) (Yeh et al, 1995 and Hwang et al., 1996). Having a model experimental system for in vitro adipogenesis of human cells would provide for discoveries in this area.
-2a-Recently it has been reported that leptin may serve as a hormone that regulates fertility and may be the link between appropriate body weight and reproductive physiology (Chehab et al. 1996). Both underweight and overweight women have difficulty in conceiving and this is likely associated with hormonal imbalance in the body of these individuals. The connection between body weight, fertility and the leptin produced by adipocytes has been suspected and now tested in mice. When obese mice, which normally do not produce offspring without transplanting the ovaries to surrogate females, were injected with leptin, there body weight fell dramatically and they were able to give birth to their own litters (Chehab et al, 1996).
A variety of cell types have been shown to produce lipid containing vesicles under specific culture conditions. For example, mouse 3T3-Ll cells derived from NIH
3T3, an immortalized mouse cell line, can be grown and cultured as a fibroblastic cell.
However, after exposure to dexamethasone and methyl-isobutylxanthine, the cells undergo differentiation which results in the production of intracellular lipid-containing vacuoles (Spiegelman and Green, 1981). Rat marrow stromal cells have been shown to undergo both osteogenic and adipogenic differentiation when cultured with fetal calf serum and dexamethasone, but the predominating cell type varies depending on conditions (Beresford et al., 1992). Specifically, when the steroid analog dexamethasone was present throughout the time course of culture, osteogenesis was favored; but when dexamethasone was present only during secondary culture, the adipogenetic pathway predominated as evidenced by lineage specific markers and cytological observation. Mouse derived CH3 lOT 1 /2 cells are a multipotential cell line that, when treated with 5-azacytidine, undergoes terminal differentiation into adipocytes, myocytes and chondrocytes. The 5-azacytidine causes inhibition of DNA
methylation and thus causes the activation of a few genes responsible for commitment to these lineages (Konieczny and Emerson, 1984).
In one aspect of the present invention, there is provided a composition which comprises mesenchymal stem cells which have been isolated from a human and which have potential to differentiate into cells of more than one connective tissue type and a substance in an amount effective to induce said stem cells to differentiate into adipogenic lineage cells, wherein the substance which induces said stem cells to differentiate into the adipogenic lineage cells comprises a glucocorticoid and a compound which elevates intracellular levels of cAMP.
In a further aspect, there is provided a process for inducing a human mesenchymal stem cells ex vivo to differentiate into adipocytes, comprising: contacting human mesenchymal stem cells with (i) a glucocorticoid and (ii) a compound which elevates intracellular levels of cAMP, said glucocorticoid and compound being employed in an amount sufficient to induce human mesenchymal stem cells to differentiate into adipocytes.
In a further aspect of the present invention, there is provided a composition and method for inducing human mesenchymal stem cells to preferentially differentiate into the adipogenic lineage, i.e., to differentiate into adipocytes.
In a further aspect, there is provided a composition which comprises mesenchymal stem cells which have been isolated from a human and which have potential to differentiate into cells of more than one connective tissue type and a substance in an amount effective to induce said stem cells to differentiate into adipogenic lineage cells.
In a further aspect, there is provided a process for inducing human mesenchymal stem cells (hMSCs) ex vivo to differentiate into adipocytes, comprising: contacting human mesenchymal stem cells with (i) a glucocorticoid and (ii) a compound which elevates intracellular levels of cAMP, said glucocorticoid and said compound which elevates intracellular levels of cAMP being employed in an amount sufficient to induce human mesenchymal stem cells to differentiate into adipocytes.
In a further aspect, there is provided a process for inducing human mesenchymal stem cells ex vivo to differentiate into adipocytes, comprising: contacting human mesenchymal stem cells with (i) a glucocorticoid and (ii) a compound which inhibits degradation of cAMP, said glucocorticoid and said compound which inhibits degradation of cAMP being employed in an amount sufficient to induce human mesenchymal stem cells to differentiate into adipocytes.
In a further aspect, there is provided a composition for producing adipocytes, comprising isolated human mesenchymal stem cells in a biocompatible matrix which supports the differentiation and maturation of human mesenchymal stem cells into adipocytes and a substance in an amount effective to induce said stem cells to differentiate into adipocytes, wherein the substance which induces said stem cells to differentiate into the adipogenic lineage cells comprises a glucocorticoid and a compound which elevates intracellular levels of cAMP.
In a further aspect of the present invention, there is provided use of a glucocorticoid and a compound which elevates intracellular levels of a cAMP for inducing human mesenchymal stem cells (hMSCs) to differentiate into adipocytes.
-4a-In a further aspect of the present invention, there is provided use for the manufacture of a medicament of a glucocorticoid and a compound which elevates intracellular levels of a cAMP for inducing human mesenchymal stem cells (hMSCs) to differentiate into adipocytes.
In a further aspect of the present invention, there is provided use of a glucocorticoid and a compound which inhibits degradation of cAMP for inducing human mesenchymal stem cells (hMSCs) to differentiate into adipocytes.
In a further aspect of the present invention, there is provided use of a glucocorticoid and a compound which inhibits degradation of cAMP for the manufacture of a medicament for inducing human mesenchymal stem cells (hMSCs) to differentiate into adipocytes.
Applicant has found that mesenchymal stem cells and in particular human mesenchymal stem cells (hMSC) can be directed to differentiate into adipocytes by treating the human mesenchymal stem cells with (i) a glucocorticoid and (ii) a compound which elevates intracellular cAMP levels by either upregulating cAMP production or by inhibiting degradation of cAMP; in particular a compound which inhibits compound(s) which degrade cAMP.
In a preferred aspect, the human mesenchymal stem cells are treated with a glucocorticoid and a compound which inhibits the activity of a compound which degrades cAMP; in particular a phosphodiesterase inhibitor. The cells are subsequently cultured in media containing insulin and fetal bovine serum.
-4b-Human mesenchymal stem cells, as well as their isolation and expansion, have been described in U.S. Patent No. 5,486,359. As known in the art, human mesenchymal stem cells are capable of producing two or more different types (lineages) of mesenchymal cells or tissues and in particular connective tissue. The present invention provides a method for generating adipocytes from primary human mesenchymal stem cells (hMSCs) in a predictable and reproducible manner.
The invention is unique in that it involves human cells in primary and passaged cultures rather than transformed or immortalized cell lines that are predetermined to enter the adipogenic pathway. hMSCs are capable of entering multiple lineages including the osteocytic, chondrocytic, myocytic, tendonocytic and stromogenic lineages and the present invention provides a method and composition for inducing hMSC's to differentiate into adipocytes. In a preferred aspect, in accordance with the present invention, hMSC's are induced to differentiate into essentially only adipocytes, i.e., there is no essential production or commitment to cells of other mesenchymal lineages.
-4c-The method may also be used for generating adipocytes from MSCs from other species such as rabbit, dog, rat and mouse.
The invention also provides methods to purify the adipocytes to obtain a highly purified population.
The method of the invention for the in vitro differentiation of human mesenchymal stem cells preferably derived from bone marrow into adipoblastic or adipocytic cells is useful to investigators wishing to study this developmental program in human cells in vitro. A better understanding of diseases of energy metabolism including obesity and obesity-related diabetes will also result from studies of the differentiation of mesenchymal stem cells to adipocytes. While a cellular and biochemical basis for obesity has long been suspected, advancements have been slow due to a lack of model systems with biochemical and molecular tools for study.
Recent dramatic breakthroughs in the molecular basis of adipogenesis have opened new avenues towards understanding this pathway of mesenchymal cell differentiation, although a human model system such as the one described here has been lacking. The method will also have utility in the isolation and preparation of adipocytes for implantation into a patient for the purpose of tissue augmentation following trauma or cosmetic surgery.
Brief Description of the Drawings Figures lA-lB show that when human MSCs are treated in accordance with the invention, they undergo differentiation to the adipogenic lineage. Figure 1A
shows hMSCs (4X) cultured in normal hMSC media for the same period of time as Figure 1B.
There is no evidence of lipid containing vacuoles and the cells maintain the appearance of fibroblasts at high density. In Figure lB are hMSCs that were allowed to become confluent and then maintained in normal media for 10 days prior to adding the Adipogenic Induction media (containing methylisobutylxanthine and dexamethasone) for 48 hrs, and then changed to the insulin-containing adipocyte maintenance media for an additional 2 weeks. The lipid vacuoles are first apparent at about 5-7 days but increase in size and abundance over time.
Figure 2A shows a similar control culture as Figure 1A at higher magnification (20X). Figure 2B show a culture of confluent hMSCs that were subjected to Adipogenic Induction media for 48 hours and then maintained in the Adipogenic Maintenance media for 14 days. The many lipid containing vacuoles of adipocytes are evident in a large proportion of the cells.
Figure 3 shows the results of culturing hMSCs under a variety of conditions, only one of which shows a high degree of adipogenic differentiation. All photos are at lOX magnification. Figure 3A shows a culture of hMSCs maintained in normal hMSC
culture media alone. The cells grow with a fibroblastic morphology. Figure 3B
shows a similar culture that was treated with Adipogenic Induction media for 48 hours and then with Adipogenic Maintenance media for an additional 14 days with media changes every 3 days. The adipogenic cells, perhaps as many as 30-35% of the cells, are evident as they contain the large refractile lipid vacuoles. Figure 3C shows a culture of hMSCs that were maintained in the Adipogenic Maintenance media for 14 days but was never subjected to the dexamethasone/methyl isobutylxanthine treatment. The cells maintain a flat morphological appearance with no evident vacuoles. Figure 3D shows a culture of hMSCs that were treated with normal hMSC media containing 1 M
dexamethasone for 48 hours and then cultured for 14 days in the Adipogenic Maintenance media. The cells are disorganized but show very few, if any, lipid vaculoes. Figure 3E
shows a culture of hMSCs that was treated with normal hMSC media containing 0.5 m.
methyl-isobutylxanthine for 48 hours and then was maintained for 14 days in the Adipogenic Maintenance media. The cells retain a flat fibroblastic phenotype. Figure 3F
shows a culture of hMSCs that was treated with a media that induces the cells to differentiate along a osteogenic pathway. This media contains 0.1 M dexamethasone, 10 mM
13-glycerol phosphate and 50 M ascorbic acid 2-phosphate. The presence of refractile osteoid material is evident but no large lipid vacuoles.
In a further aspect, there is provided a process for inducing a human mesenchymal stem cells ex vivo to differentiate into adipocytes, comprising: contacting human mesenchymal stem cells with (i) a glucocorticoid and (ii) a compound which elevates intracellular levels of cAMP, said glucocorticoid and compound being employed in an amount sufficient to induce human mesenchymal stem cells to differentiate into adipocytes.
In a further aspect of the present invention, there is provided a composition and method for inducing human mesenchymal stem cells to preferentially differentiate into the adipogenic lineage, i.e., to differentiate into adipocytes.
In a further aspect, there is provided a composition which comprises mesenchymal stem cells which have been isolated from a human and which have potential to differentiate into cells of more than one connective tissue type and a substance in an amount effective to induce said stem cells to differentiate into adipogenic lineage cells.
In a further aspect, there is provided a process for inducing human mesenchymal stem cells (hMSCs) ex vivo to differentiate into adipocytes, comprising: contacting human mesenchymal stem cells with (i) a glucocorticoid and (ii) a compound which elevates intracellular levels of cAMP, said glucocorticoid and said compound which elevates intracellular levels of cAMP being employed in an amount sufficient to induce human mesenchymal stem cells to differentiate into adipocytes.
In a further aspect, there is provided a process for inducing human mesenchymal stem cells ex vivo to differentiate into adipocytes, comprising: contacting human mesenchymal stem cells with (i) a glucocorticoid and (ii) a compound which inhibits degradation of cAMP, said glucocorticoid and said compound which inhibits degradation of cAMP being employed in an amount sufficient to induce human mesenchymal stem cells to differentiate into adipocytes.
In a further aspect, there is provided a composition for producing adipocytes, comprising isolated human mesenchymal stem cells in a biocompatible matrix which supports the differentiation and maturation of human mesenchymal stem cells into adipocytes and a substance in an amount effective to induce said stem cells to differentiate into adipocytes, wherein the substance which induces said stem cells to differentiate into the adipogenic lineage cells comprises a glucocorticoid and a compound which elevates intracellular levels of cAMP.
In a further aspect of the present invention, there is provided use of a glucocorticoid and a compound which elevates intracellular levels of a cAMP for inducing human mesenchymal stem cells (hMSCs) to differentiate into adipocytes.
-4a-In a further aspect of the present invention, there is provided use for the manufacture of a medicament of a glucocorticoid and a compound which elevates intracellular levels of a cAMP for inducing human mesenchymal stem cells (hMSCs) to differentiate into adipocytes.
In a further aspect of the present invention, there is provided use of a glucocorticoid and a compound which inhibits degradation of cAMP for inducing human mesenchymal stem cells (hMSCs) to differentiate into adipocytes.
In a further aspect of the present invention, there is provided use of a glucocorticoid and a compound which inhibits degradation of cAMP for the manufacture of a medicament for inducing human mesenchymal stem cells (hMSCs) to differentiate into adipocytes.
Applicant has found that mesenchymal stem cells and in particular human mesenchymal stem cells (hMSC) can be directed to differentiate into adipocytes by treating the human mesenchymal stem cells with (i) a glucocorticoid and (ii) a compound which elevates intracellular cAMP levels by either upregulating cAMP production or by inhibiting degradation of cAMP; in particular a compound which inhibits compound(s) which degrade cAMP.
In a preferred aspect, the human mesenchymal stem cells are treated with a glucocorticoid and a compound which inhibits the activity of a compound which degrades cAMP; in particular a phosphodiesterase inhibitor. The cells are subsequently cultured in media containing insulin and fetal bovine serum.
-4b-Human mesenchymal stem cells, as well as their isolation and expansion, have been described in U.S. Patent No. 5,486,359. As known in the art, human mesenchymal stem cells are capable of producing two or more different types (lineages) of mesenchymal cells or tissues and in particular connective tissue. The present invention provides a method for generating adipocytes from primary human mesenchymal stem cells (hMSCs) in a predictable and reproducible manner.
The invention is unique in that it involves human cells in primary and passaged cultures rather than transformed or immortalized cell lines that are predetermined to enter the adipogenic pathway. hMSCs are capable of entering multiple lineages including the osteocytic, chondrocytic, myocytic, tendonocytic and stromogenic lineages and the present invention provides a method and composition for inducing hMSC's to differentiate into adipocytes. In a preferred aspect, in accordance with the present invention, hMSC's are induced to differentiate into essentially only adipocytes, i.e., there is no essential production or commitment to cells of other mesenchymal lineages.
-4c-The method may also be used for generating adipocytes from MSCs from other species such as rabbit, dog, rat and mouse.
The invention also provides methods to purify the adipocytes to obtain a highly purified population.
The method of the invention for the in vitro differentiation of human mesenchymal stem cells preferably derived from bone marrow into adipoblastic or adipocytic cells is useful to investigators wishing to study this developmental program in human cells in vitro. A better understanding of diseases of energy metabolism including obesity and obesity-related diabetes will also result from studies of the differentiation of mesenchymal stem cells to adipocytes. While a cellular and biochemical basis for obesity has long been suspected, advancements have been slow due to a lack of model systems with biochemical and molecular tools for study.
Recent dramatic breakthroughs in the molecular basis of adipogenesis have opened new avenues towards understanding this pathway of mesenchymal cell differentiation, although a human model system such as the one described here has been lacking. The method will also have utility in the isolation and preparation of adipocytes for implantation into a patient for the purpose of tissue augmentation following trauma or cosmetic surgery.
Brief Description of the Drawings Figures lA-lB show that when human MSCs are treated in accordance with the invention, they undergo differentiation to the adipogenic lineage. Figure 1A
shows hMSCs (4X) cultured in normal hMSC media for the same period of time as Figure 1B.
There is no evidence of lipid containing vacuoles and the cells maintain the appearance of fibroblasts at high density. In Figure lB are hMSCs that were allowed to become confluent and then maintained in normal media for 10 days prior to adding the Adipogenic Induction media (containing methylisobutylxanthine and dexamethasone) for 48 hrs, and then changed to the insulin-containing adipocyte maintenance media for an additional 2 weeks. The lipid vacuoles are first apparent at about 5-7 days but increase in size and abundance over time.
Figure 2A shows a similar control culture as Figure 1A at higher magnification (20X). Figure 2B show a culture of confluent hMSCs that were subjected to Adipogenic Induction media for 48 hours and then maintained in the Adipogenic Maintenance media for 14 days. The many lipid containing vacuoles of adipocytes are evident in a large proportion of the cells.
Figure 3 shows the results of culturing hMSCs under a variety of conditions, only one of which shows a high degree of adipogenic differentiation. All photos are at lOX magnification. Figure 3A shows a culture of hMSCs maintained in normal hMSC
culture media alone. The cells grow with a fibroblastic morphology. Figure 3B
shows a similar culture that was treated with Adipogenic Induction media for 48 hours and then with Adipogenic Maintenance media for an additional 14 days with media changes every 3 days. The adipogenic cells, perhaps as many as 30-35% of the cells, are evident as they contain the large refractile lipid vacuoles. Figure 3C shows a culture of hMSCs that were maintained in the Adipogenic Maintenance media for 14 days but was never subjected to the dexamethasone/methyl isobutylxanthine treatment. The cells maintain a flat morphological appearance with no evident vacuoles. Figure 3D shows a culture of hMSCs that were treated with normal hMSC media containing 1 M
dexamethasone for 48 hours and then cultured for 14 days in the Adipogenic Maintenance media. The cells are disorganized but show very few, if any, lipid vaculoes. Figure 3E
shows a culture of hMSCs that was treated with normal hMSC media containing 0.5 m.
methyl-isobutylxanthine for 48 hours and then was maintained for 14 days in the Adipogenic Maintenance media. The cells retain a flat fibroblastic phenotype. Figure 3F
shows a culture of hMSCs that was treated with a media that induces the cells to differentiate along a osteogenic pathway. This media contains 0.1 M dexamethasone, 10 mM
13-glycerol phosphate and 50 M ascorbic acid 2-phosphate. The presence of refractile osteoid material is evident but no large lipid vacuoles.
Figure 4A shows a culture of hMSCs subjected to the Adipogenic Induction media for 48 hours and then cultured for 14 days in the Adipogenic Maintenance media.
The large lipid vacuoles are evident in this bright field image. The lipids can also be revealed by using a fluorescent lipid soluble dye, such as Nile Red, and viewing by epifluorescence illumination as shown in Figure 4B. Thus, the adipogenic cells can also be identified using vital dyes and histological stains that label the lipid vacuoles.
Figure 5A shows hMSCs in culture which were not treated with Adipogenic Induction media but which were cultured, fixed and stained at the same time as the adipogenic cultures shown in 5B and 5C.
Figure 5B shows hMSCs that were treated once for 48 hours with Adipogenic Induction media and then cultured for an additional three weeks in Adipogenic Maintenance media and then fixed in neutral buffered formalin and stained with Oil Red 0, a lipid soluble dye that accumulates in the fat droplets.
Figure 5C shows a dish of hMSCs that was retreated with fresh Adipogenic Induction media for a second and third 48 hour period to induce more hMSCs to become adipogenic. As many as 30-40% of the cells were converted to adipocytes by the three induction treatments when viewed two weeks after the third treatment. Panels 5A-5C were all stained with Oil Red O.
Figure 5D the transcription factor CAAT/enhancer binding protein (or C/EBPix) is expressed at high levels in the adipogenic hMSCs as shown by this western blot using an antibody specific for the 34 kd a isoform of C/EBP.
Figure 5E the fatty acid binding protein aP2 shows high levels of expression in the adipogenic hMSCs as shown by this western blot using an antibody specific for the 14 kd adipocyte specific form of P2.
The large lipid vacuoles are evident in this bright field image. The lipids can also be revealed by using a fluorescent lipid soluble dye, such as Nile Red, and viewing by epifluorescence illumination as shown in Figure 4B. Thus, the adipogenic cells can also be identified using vital dyes and histological stains that label the lipid vacuoles.
Figure 5A shows hMSCs in culture which were not treated with Adipogenic Induction media but which were cultured, fixed and stained at the same time as the adipogenic cultures shown in 5B and 5C.
Figure 5B shows hMSCs that were treated once for 48 hours with Adipogenic Induction media and then cultured for an additional three weeks in Adipogenic Maintenance media and then fixed in neutral buffered formalin and stained with Oil Red 0, a lipid soluble dye that accumulates in the fat droplets.
Figure 5C shows a dish of hMSCs that was retreated with fresh Adipogenic Induction media for a second and third 48 hour period to induce more hMSCs to become adipogenic. As many as 30-40% of the cells were converted to adipocytes by the three induction treatments when viewed two weeks after the third treatment. Panels 5A-5C were all stained with Oil Red O.
Figure 5D the transcription factor CAAT/enhancer binding protein (or C/EBPix) is expressed at high levels in the adipogenic hMSCs as shown by this western blot using an antibody specific for the 34 kd a isoform of C/EBP.
Figure 5E the fatty acid binding protein aP2 shows high levels of expression in the adipogenic hMSCs as shown by this western blot using an antibody specific for the 14 kd adipocyte specific form of P2.
Figure 6A shows the isolated adipogenic hMSCs that attached to the uppermost surface. The population is composed of greater than 99% adipogenic cells as evidenced by the lipid droplets in every cell.
Figure 6B shows the non-adipogenic hMSCs that settled to the lower surface of the flask. Very few cells containing lipid droplets were present on the lower surface.
These non-adipogenic cells could be treated with trypsin/EDTA and replated to another dish and be shown to retain adipogenic potential (data not shown), indicating that they remain as mesenchymal stem cells, capable of lineage progression.
Figure 7 shows an example of hMSCs grown in stabilized collagen gel matrix and then induced to differentiate into adipocytes. The cells have been stained with Nile Red fluorescent dye that accumulates in the lipid vacuoles which are visualized by ultraviolet illumination. Only the lipid deposits in the cells are visible and many of the adipocytes are out of the plane of focus in the three dimensional matrix.
Detailed Description of the Preferred Embodiments As noted above, one aspect of the invention provides a composition which comprises an isolated, homogeneous population of human mesenchymal stem cells which have the potential to differentiate into cells of more than one mesenchymal tissue type, and a substance which induces cells from the mesenchymal stem cell population to differentiate into the adipogenic lineage.
In a preferred embodiment of this aspect of the invention mesenchymal stem cells are induced to differentiate into the adipogenic lineage by use of a glucocorticoid and a compound which either elevates intracellular levels of cAMP, for example, a cAMP
analog or a compound which stimulates production of cAMP or inhibits degradation of cAMP; in particular a phosphodiesterase inhibitor.
Figure 6B shows the non-adipogenic hMSCs that settled to the lower surface of the flask. Very few cells containing lipid droplets were present on the lower surface.
These non-adipogenic cells could be treated with trypsin/EDTA and replated to another dish and be shown to retain adipogenic potential (data not shown), indicating that they remain as mesenchymal stem cells, capable of lineage progression.
Figure 7 shows an example of hMSCs grown in stabilized collagen gel matrix and then induced to differentiate into adipocytes. The cells have been stained with Nile Red fluorescent dye that accumulates in the lipid vacuoles which are visualized by ultraviolet illumination. Only the lipid deposits in the cells are visible and many of the adipocytes are out of the plane of focus in the three dimensional matrix.
Detailed Description of the Preferred Embodiments As noted above, one aspect of the invention provides a composition which comprises an isolated, homogeneous population of human mesenchymal stem cells which have the potential to differentiate into cells of more than one mesenchymal tissue type, and a substance which induces cells from the mesenchymal stem cell population to differentiate into the adipogenic lineage.
In a preferred embodiment of this aspect of the invention mesenchymal stem cells are induced to differentiate into the adipogenic lineage by use of a glucocorticoid and a compound which either elevates intracellular levels of cAMP, for example, a cAMP
analog or a compound which stimulates production of cAMP or inhibits degradation of cAMP; in particular a phosphodiesterase inhibitor.
T -- --Preferred examples of the glucocorticoid are selected from the group consisting of dexamethasone, hydrocortisone, cortisone, etc.
Preferred examples of the substance which elevate intracellular cAMP levels or are cAMP analogs include dibutyryl-cAMP, 8-CPT-cAMP (8-(4)-chlorophenylthio)-adenosine 3', 5' cyclic monophosphate; 8-bromo-cAMP; dioctanoyl-cAMP, Forskolin, etc.
Preferred examples of the substance which inhibits cAMP degradation by inhibiting the activity of phosphodiesterase is selected from the group consisting of methyl isobutylxanthine, theophylline; caffeine, and indomethacin.
The compound which elevates levels of cAMP and the glucocorticoid are used in amounts which are effective to induce hMSCs to differentiate into adipocytes. The cAMP regulating compound and glucocorticoid may be added to the hMSCs separately or in admixture with each other.
In general, the glucocorticoid is used in a concentration from about 0.1 to 10 micromolar, preferably from about 0.5 to 2 micromolar.
When employing a compound which inhibits degradation of cAMP, such a compound is generally employed in a concentration of about 0.1 to 10 millimolar and preferably from about 0.2 to 2 millimolar.
When employing a compound which upregulates cAMP production, such compound is generally employed in a concentration of from about 0.1 to 100 micromolar, preferably from about 0.5 to 10 micromolar.
It is to be understood that the above amounts are representative and the scope of the invention is not to be limited thereby.
Preferred examples of the substance which elevate intracellular cAMP levels or are cAMP analogs include dibutyryl-cAMP, 8-CPT-cAMP (8-(4)-chlorophenylthio)-adenosine 3', 5' cyclic monophosphate; 8-bromo-cAMP; dioctanoyl-cAMP, Forskolin, etc.
Preferred examples of the substance which inhibits cAMP degradation by inhibiting the activity of phosphodiesterase is selected from the group consisting of methyl isobutylxanthine, theophylline; caffeine, and indomethacin.
The compound which elevates levels of cAMP and the glucocorticoid are used in amounts which are effective to induce hMSCs to differentiate into adipocytes. The cAMP regulating compound and glucocorticoid may be added to the hMSCs separately or in admixture with each other.
In general, the glucocorticoid is used in a concentration from about 0.1 to 10 micromolar, preferably from about 0.5 to 2 micromolar.
When employing a compound which inhibits degradation of cAMP, such a compound is generally employed in a concentration of about 0.1 to 10 millimolar and preferably from about 0.2 to 2 millimolar.
When employing a compound which upregulates cAMP production, such compound is generally employed in a concentration of from about 0.1 to 100 micromolar, preferably from about 0.5 to 10 micromolar.
It is to be understood that the above amounts are representative and the scope of the invention is not to be limited thereby.
Although one of the compounds which is employed to induce hMSCs to differentiate into adipocytes is one which regulates cAMP (either one which is known to upregulate cAMP production or one which prevents degradation of cAMP), the scope of the invention is not limited to any particular mechanism of action. Thus, for example, even though one of the compounds which may be used in the present invention is a phosphodiesterase inhibitor which is known to inhibit degradation of cAMP
by inhibiting phosphodiesterase degradation of cAMP, the invention is not limited to a mechanism of action which is dependent upon preventing degradation of cAMP.
Thus, for example, the phosphodiesterase inhibitor may be effective for inducing differentiation of hMSCs to adipocytes by a mechanism of action other than inhibiting degradation of cAMP.
Compounds in addition to (i) a glucocorticoid and (ii) a cAMP regulator may be used for inducing hMSCs to differentiate into adipocytes. Thus, for example, in a preferred embodiment insulin is also employed in conjunction with the cAMP
regulator and glucocorticoid.
In a preferred embodiment, there is provided a composition for inducing hMSCs to differentiate into adipocytes which is comprised of (i) a glucocorticoid, (ii) a compound which regulates cAMP and in particular a compound which inhibits cAMP
degradation such as, a phosphodiesterase inhibitor, (iii) insulin or insulin-like growth factor and (iv) glucose.
The addition of compounds as hereinabove described to induce differentiation of hMSCs to adipocytes in accordance with the invention does not require that all of the treated hMSCs be induced to differentiate into adipocytes. Thus, in accordance with an aspect of the present invention there is produced a composition comprised of human mesenchymal stem cells and adipocytes wherein based on the two components the adipocytes are present in an amount of at least 5 wt. % and preferably at least 15 wt.
by inhibiting phosphodiesterase degradation of cAMP, the invention is not limited to a mechanism of action which is dependent upon preventing degradation of cAMP.
Thus, for example, the phosphodiesterase inhibitor may be effective for inducing differentiation of hMSCs to adipocytes by a mechanism of action other than inhibiting degradation of cAMP.
Compounds in addition to (i) a glucocorticoid and (ii) a cAMP regulator may be used for inducing hMSCs to differentiate into adipocytes. Thus, for example, in a preferred embodiment insulin is also employed in conjunction with the cAMP
regulator and glucocorticoid.
In a preferred embodiment, there is provided a composition for inducing hMSCs to differentiate into adipocytes which is comprised of (i) a glucocorticoid, (ii) a compound which regulates cAMP and in particular a compound which inhibits cAMP
degradation such as, a phosphodiesterase inhibitor, (iii) insulin or insulin-like growth factor and (iv) glucose.
The addition of compounds as hereinabove described to induce differentiation of hMSCs to adipocytes in accordance with the invention does not require that all of the treated hMSCs be induced to differentiate into adipocytes. Thus, in accordance with an aspect of the present invention there is produced a composition comprised of human mesenchymal stem cells and adipocytes wherein based on the two components the adipocytes are present in an amount of at least 5 wt. % and preferably at least 15 wt.
%. The amount of adipocytes may be up to 50 wt. % or higher, based on the two components.
In accordance with a preferred embodiment, the composition which is generated is essentially free of committed cells of the mesenchymal lineage other than adipocytes.
In a particular preferred embodiment, there are less than one percent of committed cells of the mesenchymal lineage other than adipocytes, and more preferably, less than 0.1 %
and most preferably no committed cells of the mesenchymal lineage other than adipocytes.
Although treatment of hMSCs in accordance with the invention produces a mixture of adipocytes and undifferentiated hMSCs, the produced adipocytes may be recovered from the mixture to produce an isolated population of adipocytes.
Representative procedures for recovering adipocytes are described in the examples which form a part of this application.
In accordance with an aspect of the present invention, hMSCs may be treated to induce differentiation into adipocytes in a manner such that such differentiation is effected in vitro or in vivo.
Thus, for example, hMSCs may be admixed with compounds as hereinabove described which induce differentiation into hMSCs and the resulting mixture employed in vivo to induce differentiation to adipocytes in vivo. Thus, for example, the mixture without culturing in vitro for a period of time to induce differentiation in vitro may be employed in a suitable matrix (for example of the type hereinafter described) to induce differentiation of the hMSCs to adipocytes in vivo.
Thus, in accordance with an aspect of the present invention there is provided a composition comprised of human mesenchymal stem cells, a glucocorticoid and a cAMP
regulator (a compound(s) which upregulates cAMP production or inhibits cAMP
In accordance with a preferred embodiment, the composition which is generated is essentially free of committed cells of the mesenchymal lineage other than adipocytes.
In a particular preferred embodiment, there are less than one percent of committed cells of the mesenchymal lineage other than adipocytes, and more preferably, less than 0.1 %
and most preferably no committed cells of the mesenchymal lineage other than adipocytes.
Although treatment of hMSCs in accordance with the invention produces a mixture of adipocytes and undifferentiated hMSCs, the produced adipocytes may be recovered from the mixture to produce an isolated population of adipocytes.
Representative procedures for recovering adipocytes are described in the examples which form a part of this application.
In accordance with an aspect of the present invention, hMSCs may be treated to induce differentiation into adipocytes in a manner such that such differentiation is effected in vitro or in vivo.
Thus, for example, hMSCs may be admixed with compounds as hereinabove described which induce differentiation into hMSCs and the resulting mixture employed in vivo to induce differentiation to adipocytes in vivo. Thus, for example, the mixture without culturing in vitro for a period of time to induce differentiation in vitro may be employed in a suitable matrix (for example of the type hereinafter described) to induce differentiation of the hMSCs to adipocytes in vivo.
Thus, in accordance with an aspect of the present invention there is provided a composition comprised of human mesenchymal stem cells, a glucocorticoid and a cAMP
regulator (a compound(s) which upregulates cAMP production or inhibits cAMP
degradation). Such a composition may be employed to produce adipocytes in vitro or may be employed to induce differentiation of hMSCs in vivo.
The ability to generate large percentages of adipogenic cells from a population of hMSCs will allow greater numbers of cells for implantation or research studies.
Fewer hMSCs would be needed as starting material. By repeating the adipogenic induction step more times, it should be possible to induce most of the hMSCs in a population to adipocytes. In the case where there is a mixture of cells, adipogenic hMSCs can easily be isolated by their buoyant density. The isolation of a highly enriched population of adipocytes from cultured hMSCs will also allow for a detailed characterization of the adipocyte phenotype The adipocytes can be used with a variety of materials to form a composition for purposes such as reconstructive surgery. The cells may be combined with a biomatrix to form a two dimensional or three dimensional material as needed. Surgeons routinely use fat pads and fatty tissues from remote sites to build up an area where tissue has been removed. This often involves a separate procedure with its inherent risks. As an alternative, hMSCs could be isolated from the patient and grown in culture.
The hMSCs could then be mixed with a biocompatible material such as collagen, collagen sponge, alginate, polylactic acid material etc. to form a composite. The composite would then be treated to induce adipogenic differentiation of the MSCs in vitro for 1-3 weeks, then implanted when needed. For example, adipogenic MSCs could be mixed with a solubilized collagen or other biomaterial which is then allowed to gel to form a three dimensional composite that could be used for breast augmentation following mastectomy. Such a composite could be formed or sculpted to the appropriate size and shape. Another composition includes the culturing of hMSCs on the acellular skin matrix that is currently on the market such as the product by LifeCell Corporation. In this format the cells would be cultured to populate the matrix and then caused to differentiate as described. The matrix with the adipogenic cells could then be cut by the surgeon to fit the site of reconstruction. As an alternative hMSCs could be induced to -r become adipocytes prior to their introduction into the biocompatible materials. As another alternative, hMSCs in combination with compounds which promote differentiation into adipocytes may be used with a biomatrix as described without culturing for a period of time to induce differentiation whereby differentiation is induced in whole or in part in vivo.
Similar to their use in reconstructive surgery, adipogenic hMSCs will be of use in elective cosmetic surgery in much the same way; to build up underlying tissue below the skin with a composite of autologous cells and biocompatible material.
The invention will be further described with respect to the following examples;
however, the scope of the invention is not to be limited thereby. Unless otherwise described percentages and parts are by weight.
Biochemical Markers of Adipocytes A number of molecules that are specific markers of adipocytes have been described in the literature that will be useful to characterize the adipocytes derived from hMSCs. These include enzymes involved in the interconversion of fatty acids to triglycerides such as stearoyl-CoA-desaturase (SCDI) or the insulin responsive glucose transporter (GLUT4). The product of the ob gene, leptin is a 16,000 molecular weight polypeptide that is only expressed in pre-adipose cells or adipose tissue. The expression of CCAAT enhancer binding protein, C/EBP, has been shown to precede the expression of several markers of adipogenic differentiation and it is thought to play a key role in adipocyte development. Another marker is 422 adipose P2 (422/aP2), a protein whose expression is enhanced during adipocyte differentiation (Cheneval, et al, 1991.). This differentiation pathway is thought also to involve peroxisome proliferation-activated receptor -y2 (PPAR'y2), which is involved in the initiation of transcription of adipocyte genes (Tontonoz, et al, 1994). Studies using these markers and the described methods will allow a more detailed analysis of the lineage progression of mesenchymal stem cell to adipocyte differentiation.
The ability to generate large percentages of adipogenic cells from a population of hMSCs will allow greater numbers of cells for implantation or research studies.
Fewer hMSCs would be needed as starting material. By repeating the adipogenic induction step more times, it should be possible to induce most of the hMSCs in a population to adipocytes. In the case where there is a mixture of cells, adipogenic hMSCs can easily be isolated by their buoyant density. The isolation of a highly enriched population of adipocytes from cultured hMSCs will also allow for a detailed characterization of the adipocyte phenotype The adipocytes can be used with a variety of materials to form a composition for purposes such as reconstructive surgery. The cells may be combined with a biomatrix to form a two dimensional or three dimensional material as needed. Surgeons routinely use fat pads and fatty tissues from remote sites to build up an area where tissue has been removed. This often involves a separate procedure with its inherent risks. As an alternative, hMSCs could be isolated from the patient and grown in culture.
The hMSCs could then be mixed with a biocompatible material such as collagen, collagen sponge, alginate, polylactic acid material etc. to form a composite. The composite would then be treated to induce adipogenic differentiation of the MSCs in vitro for 1-3 weeks, then implanted when needed. For example, adipogenic MSCs could be mixed with a solubilized collagen or other biomaterial which is then allowed to gel to form a three dimensional composite that could be used for breast augmentation following mastectomy. Such a composite could be formed or sculpted to the appropriate size and shape. Another composition includes the culturing of hMSCs on the acellular skin matrix that is currently on the market such as the product by LifeCell Corporation. In this format the cells would be cultured to populate the matrix and then caused to differentiate as described. The matrix with the adipogenic cells could then be cut by the surgeon to fit the site of reconstruction. As an alternative hMSCs could be induced to -r become adipocytes prior to their introduction into the biocompatible materials. As another alternative, hMSCs in combination with compounds which promote differentiation into adipocytes may be used with a biomatrix as described without culturing for a period of time to induce differentiation whereby differentiation is induced in whole or in part in vivo.
Similar to their use in reconstructive surgery, adipogenic hMSCs will be of use in elective cosmetic surgery in much the same way; to build up underlying tissue below the skin with a composite of autologous cells and biocompatible material.
The invention will be further described with respect to the following examples;
however, the scope of the invention is not to be limited thereby. Unless otherwise described percentages and parts are by weight.
Biochemical Markers of Adipocytes A number of molecules that are specific markers of adipocytes have been described in the literature that will be useful to characterize the adipocytes derived from hMSCs. These include enzymes involved in the interconversion of fatty acids to triglycerides such as stearoyl-CoA-desaturase (SCDI) or the insulin responsive glucose transporter (GLUT4). The product of the ob gene, leptin is a 16,000 molecular weight polypeptide that is only expressed in pre-adipose cells or adipose tissue. The expression of CCAAT enhancer binding protein, C/EBP, has been shown to precede the expression of several markers of adipogenic differentiation and it is thought to play a key role in adipocyte development. Another marker is 422 adipose P2 (422/aP2), a protein whose expression is enhanced during adipocyte differentiation (Cheneval, et al, 1991.). This differentiation pathway is thought also to involve peroxisome proliferation-activated receptor -y2 (PPAR'y2), which is involved in the initiation of transcription of adipocyte genes (Tontonoz, et al, 1994). Studies using these markers and the described methods will allow a more detailed analysis of the lineage progression of mesenchymal stem cell to adipocyte differentiation.
Lipid soluble dyes as markers of adipocyte differentiation Lipid soluble dyes are available to stain lipid vaculoes in adipocytes. These include Nile Red, Nile Blue, Sudan Black and Oil Red O'. among others. Each of these hydrophobic dyes has a propensity to accumulate in the lipid containing vaculoes of the developing adipocytes and can readily identify the adipogenie cells in populations of differentiating MSCS. At least one of these dyes can be used to isolate adipocytes from non-differentiated cells using a fluorescence activated cell soner (FACS). An example of the use of Nile Red to identify adipogenic hMSCs is shown in Figure 4.
Example Generation of Adipocvtes from Human MSCs Human MSCs are isolated from the red bone marrow of volunteer donors as described in U.S. 5,486,359.
The cells are grown until colonies are well established and at this point the cells are subcultured (1 to 3) or they can be taken to assay for in vitro adipogenesis. For the adipogenesis assay, hMSCs are subcultured into 35 nun tissue culture dishes at 100,000 cells per dish and fed with 2 milliliters normal hMSC Media (Dulbecco's Modified Eagle's Media (DMEM), 10% selected Fetal Bovine Serum (FBS) and antibiotic/antimycotic mixture (1X) (Life Technologies, Inc.)) and cells are maintained at 37 C, 5% CO2 and 90% humidity. The cells are refed with the fresh media every third day and are allowed to multiply and become confluent. The cells are maintained after reaching confluence by refeeding every third day and this time period of post confluence culturing enhances the adipogenic response in the next step (at least out to 14 days). The differentiation into adipocytes is initiated by changing the media to 2 ml of Adipogenic Induction Media (DMEM with 10% fetal bovine serum containing 10 g/ml insulin (human recombinant, Boehringer Mannheim Corp.), 0.5 mM methyl isobutylxanthine (MIX)(Sigma Chemical Co.), 1 uM dexamethasone (Dex)(Sigma Chemical Co.)). This media is left on the cells for 48 bra with cells maintained at 37 C, 5% CO2, 90 % humidity and is then replaced with Adipogenic Maintenance Media *Trade-mark (DMEM containing 10% FBS and 10 g/ml insulin). The medium is changed every 3-days. The hMSCs begin to show small lipid vacuoles in 3-7 days and these enlarge and become more numerous over time, out to at least 30 days. There are several variations that have been successfully tried.
When human MSCs are treated as described above, they undergo differentiation to the adipogenic lineage, as shown in Figure 1. Figure IA shows hMSCs (4X) cultured in normal hMSC media for the same period of time as Figure 1B. There is no evidence of lipid containing vacuoles and the cells maintain the appearance of fibroblasts at high density. In Figure 1B are hMSCs that were allowed to become confluent and then maintained for 10 days prior to adding the Adipogenic Induction Media for 48 hrs, and then changed to the Adipogenic Maintenance Media for an additional 2 weeks.
The lipid vacuoles are first apparent at about 3-7 days but increase in size and abundance over time. Figure 2A shows a similar control culture as Figure 1A at higher magnification (20X). Figure 2B show a culture of confluent hMSCs that were subjected to Adipogenic Induction Media for 48 hours and then maintained in Adipogenic Maintenance Media for 14 days. The many lipid containing vacuoles of adipocytes are evident in a large proportion of the cells.
Figure 3 shows the results of culturing hMSCs under a variety of conditions, only one of which shows a high degree of adipogenic differentiation. All photos are at lOX magnification. Figure 3A shows a culture of hMSCs maintained in normal hMSC
culture media with no additives. The cells grow with a fibroblastic morphology. Figure 3B shows a similar culture that was treated with Adipogenic Induction Media for 48 hours and then with Adipogenic Maintenance Media for an additional 14 days with media changes every 3 days. The adipogenic cells, perhaps as many as 30-35 %
of the cells, are evident as they contain the large refractile lipid vacuoles. Figure 3C shows a culture of hMSCs that were maintained in the Adipogenic Maintenance Media for 14 days but was never subjected to the dexamethasone/methyl isobutylxanthine treatment.
The cells maintain a flat morphological appearance with no evident vacuoles.
Figure 3D shows a culture of hMSCs that were treated with normal hMSC media containing 1 M dexamethasone for 48 hours and then cultured for 14 days in the Adipogenic Maintenance Media. The cells are disorganized but show very few, if any, lipid vacuoles. Figure 3E shows a culture of hMSCs that was treated with normal hMSC
containing 0.5 ml. methyl isobutylxanthine during the induction period and then was maintained for 14 days in the Adipogenic Maintenance Media. The cells retain a flat fibroblastic phenotype. Figure 3F shows a culture of hMSCs that was treated with a media that induces the cells along a osteogenic pathway. This media contains 0.1 M
dexamethasone, 10 mM 13-glycerol phosphate and 50 M ascorbic acid 2-phosphate.
The presence of refractile osteoid material is evident but no large lipid vacuoles.
The adipogenic cells can also be identified using vital dyes and histological stains that label the lipid vacuoles. Figure 4A shows a culture of hMSCs subjected to the adipogenic treatment and cultured for 14 days in the Adipogenic Maintenance Media.
The large lipid vacuoles are evident in this bright field image. But the lipids can also be revealed by using a fluorescent lipid soluble dye such as Nile Red (Greenspan, et al.
1985) and viewing by epifluorescence illumination as shown in Figure 4B.
The results shown here have been reproduced several times with hMSCs derived from different donors and additional information on the method is described here.
Similar results have been obtained with hMSCs from all individuals tested (4 or more donors). The percentage of cells that become lipid containing adipocytes varies depending on the specifics of culturing. Specifically, those cells that were allowed to become completely confluent and maintained this way for up to 2 weeks prior to adipocyte induction, showed a much higher percentage of adipocytes overtime than cultures that were induced prior to confluence or at confluence. As many as 30-35 %
of the hMSCs appear adipogenic at 2 weeks post induction when treated as described herein as shown in Figure lB. hMSCs can be cultured in various sizes of culture ware with equal success so obtaining larger numbers of cells should not present any problem.
Example Generation of Adipocvtes from Human MSCs Human MSCs are isolated from the red bone marrow of volunteer donors as described in U.S. 5,486,359.
The cells are grown until colonies are well established and at this point the cells are subcultured (1 to 3) or they can be taken to assay for in vitro adipogenesis. For the adipogenesis assay, hMSCs are subcultured into 35 nun tissue culture dishes at 100,000 cells per dish and fed with 2 milliliters normal hMSC Media (Dulbecco's Modified Eagle's Media (DMEM), 10% selected Fetal Bovine Serum (FBS) and antibiotic/antimycotic mixture (1X) (Life Technologies, Inc.)) and cells are maintained at 37 C, 5% CO2 and 90% humidity. The cells are refed with the fresh media every third day and are allowed to multiply and become confluent. The cells are maintained after reaching confluence by refeeding every third day and this time period of post confluence culturing enhances the adipogenic response in the next step (at least out to 14 days). The differentiation into adipocytes is initiated by changing the media to 2 ml of Adipogenic Induction Media (DMEM with 10% fetal bovine serum containing 10 g/ml insulin (human recombinant, Boehringer Mannheim Corp.), 0.5 mM methyl isobutylxanthine (MIX)(Sigma Chemical Co.), 1 uM dexamethasone (Dex)(Sigma Chemical Co.)). This media is left on the cells for 48 bra with cells maintained at 37 C, 5% CO2, 90 % humidity and is then replaced with Adipogenic Maintenance Media *Trade-mark (DMEM containing 10% FBS and 10 g/ml insulin). The medium is changed every 3-days. The hMSCs begin to show small lipid vacuoles in 3-7 days and these enlarge and become more numerous over time, out to at least 30 days. There are several variations that have been successfully tried.
When human MSCs are treated as described above, they undergo differentiation to the adipogenic lineage, as shown in Figure 1. Figure IA shows hMSCs (4X) cultured in normal hMSC media for the same period of time as Figure 1B. There is no evidence of lipid containing vacuoles and the cells maintain the appearance of fibroblasts at high density. In Figure 1B are hMSCs that were allowed to become confluent and then maintained for 10 days prior to adding the Adipogenic Induction Media for 48 hrs, and then changed to the Adipogenic Maintenance Media for an additional 2 weeks.
The lipid vacuoles are first apparent at about 3-7 days but increase in size and abundance over time. Figure 2A shows a similar control culture as Figure 1A at higher magnification (20X). Figure 2B show a culture of confluent hMSCs that were subjected to Adipogenic Induction Media for 48 hours and then maintained in Adipogenic Maintenance Media for 14 days. The many lipid containing vacuoles of adipocytes are evident in a large proportion of the cells.
Figure 3 shows the results of culturing hMSCs under a variety of conditions, only one of which shows a high degree of adipogenic differentiation. All photos are at lOX magnification. Figure 3A shows a culture of hMSCs maintained in normal hMSC
culture media with no additives. The cells grow with a fibroblastic morphology. Figure 3B shows a similar culture that was treated with Adipogenic Induction Media for 48 hours and then with Adipogenic Maintenance Media for an additional 14 days with media changes every 3 days. The adipogenic cells, perhaps as many as 30-35 %
of the cells, are evident as they contain the large refractile lipid vacuoles. Figure 3C shows a culture of hMSCs that were maintained in the Adipogenic Maintenance Media for 14 days but was never subjected to the dexamethasone/methyl isobutylxanthine treatment.
The cells maintain a flat morphological appearance with no evident vacuoles.
Figure 3D shows a culture of hMSCs that were treated with normal hMSC media containing 1 M dexamethasone for 48 hours and then cultured for 14 days in the Adipogenic Maintenance Media. The cells are disorganized but show very few, if any, lipid vacuoles. Figure 3E shows a culture of hMSCs that was treated with normal hMSC
containing 0.5 ml. methyl isobutylxanthine during the induction period and then was maintained for 14 days in the Adipogenic Maintenance Media. The cells retain a flat fibroblastic phenotype. Figure 3F shows a culture of hMSCs that was treated with a media that induces the cells along a osteogenic pathway. This media contains 0.1 M
dexamethasone, 10 mM 13-glycerol phosphate and 50 M ascorbic acid 2-phosphate.
The presence of refractile osteoid material is evident but no large lipid vacuoles.
The adipogenic cells can also be identified using vital dyes and histological stains that label the lipid vacuoles. Figure 4A shows a culture of hMSCs subjected to the adipogenic treatment and cultured for 14 days in the Adipogenic Maintenance Media.
The large lipid vacuoles are evident in this bright field image. But the lipids can also be revealed by using a fluorescent lipid soluble dye such as Nile Red (Greenspan, et al.
1985) and viewing by epifluorescence illumination as shown in Figure 4B.
The results shown here have been reproduced several times with hMSCs derived from different donors and additional information on the method is described here.
Similar results have been obtained with hMSCs from all individuals tested (4 or more donors). The percentage of cells that become lipid containing adipocytes varies depending on the specifics of culturing. Specifically, those cells that were allowed to become completely confluent and maintained this way for up to 2 weeks prior to adipocyte induction, showed a much higher percentage of adipocytes overtime than cultures that were induced prior to confluence or at confluence. As many as 30-35 %
of the hMSCs appear adipogenic at 2 weeks post induction when treated as described herein as shown in Figure lB. hMSCs can be cultured in various sizes of culture ware with equal success so obtaining larger numbers of cells should not present any problem.
Example 2 Enhancing Adipogenic Differentiation These experiments were performed to determine whether a population of human mesenchymal stem cells growing in culture can be treated to induce adipogenic differentiation (which induces a percentage of 5-10% of the cells to become adipocytes), and then retreated at a later time to induce more of the hMSCs to differentiate.
Experiments were also performed to examine whether it is possible to purify a population of induced adipogenic cells from the mixed culture of hMSCs and adipogenic MSCs that result from the treatment with adipogenic agents. Both sets of experiments were successful as described below and in the accompanying figures.
hMSCs were induced to the adipogenic phenotype by the culturing in Adipogenic Induction Media for 48 hours as described. The media was then changed to Adipogenic Maintenance Media and cells were cultured at 37 C in a 5% CO2 atmosphere for 3 to 6 days until there were noticeable lipid droplets visible within cells.
Approximately 5-10% of the cells became adipogenic as seen in Figure 5. Figure 5A shows hMSCs in culture which were not treated with either adipogenic medium but which were cultured, fixed and stained at the same time as the adipogenic cultures shown in 5B and 5C. Figure 5B was treated once with Adipogenic Induction Media and then cultured in Adipogenic Maintenance Media for an additional three weeks and then fixed in neutral buffered formalin and stained with Oil Red 0, a lipid soluble dye that accumulates in the fat droplets. A dish of hMSCs was also retreated with fresh Adipogenic Induction Media for a second and third 48 hour period to induce more hMSCs to become adipogenic as shown in Figure 5C. As many as 30-40% of the cells were converted to adipocytes by the three induction treatments when viewed two weeks after the third treatment. Panels 5A-5C were all stained with Oil Red O.
Expression of adipogenic proteins in differentiating hMSCs.
hMSCs express adipocyte-specific proteins following differentiation. In Figures 5D and 5E, lOg of total protein lysate was resolved by SDS-PAGE, transferred to nitrocellulose and probed with antibodies for C/EPBa or aP2. In Figure 5D, the transcription factor CAAT/enhancer binding protein (or C/EPBa) is expressed at high levels in the adipogenic hMSCs as shown by this western blot using an antibody specific for the 34 kd a isoform of C/EBP. In Figure 5E, the fatty acid binding protein aP2 shows high levels of expression in the adipogenic hMSCs as shown by this western blot using an antibody specific for the 14 kd adipocyte specific form of P2.
Expression of adipogenic genes in differentiating hMSCs The expression of transcription factors that are known to be involved in adipogenic differentiation also indicates that hMSCs have become adipocytes. A
class of compounds known as peroxisome proliferators, which includes some clinically used hypolipdemic agents, can activate nuclear receptors associated with adipogenic differentiation. The peroxisome proliferator activated receptor y2 (or PPARy2), in particular, has been shown to be associated with adipogenesis. RNA blot analysis (Northern blotting) was used to identify the elevated expression of PPAR y2 RNA in hMSCs undergoing adipogenic differentiation. Total RNA was isolated from control hMSCs and adipogenic hMSCs, resolved by denaturing gel electrophoresis and transferred to nitrocellulose and probed for the expression of PPARy2 cultures hMSCs (lane 1, 10 g) or adipogenic hMSCs (lane 2, 10 g; lane 3, 20 g). As shown in Figure 5F, the PPARy2 mRNA is detected at 1.7 kb as indicated by the arrow and its expression is elevated about 5 fold in RNA from the adipogenic hMSCs.
The elevated expression of RNA for lipoprotein lipase, an enzyme responsible for hydrolysis of the tryglyceride core to monoacylglycerol and free fatty acids, indicates adipogenic differentiation of hMSCs, as shown in Figure 5G. As in 5F, 10 g of total RNA from control hMSCs (lane 1) or adipogenic hMSCs (lane 2) or 20 g of RNA from adipogenic hMSCs was resolved by denaturing gel electrophoresis, transferred to nitrocellulose and probed for the expression of LPL RNA. The mRNA
for LPL is found as two bands of 3.3 and 3.7 kb lanes 2 and 3 (the bands in 3 are slightly shifted up due to the high loading).
Experiments were also performed to examine whether it is possible to purify a population of induced adipogenic cells from the mixed culture of hMSCs and adipogenic MSCs that result from the treatment with adipogenic agents. Both sets of experiments were successful as described below and in the accompanying figures.
hMSCs were induced to the adipogenic phenotype by the culturing in Adipogenic Induction Media for 48 hours as described. The media was then changed to Adipogenic Maintenance Media and cells were cultured at 37 C in a 5% CO2 atmosphere for 3 to 6 days until there were noticeable lipid droplets visible within cells.
Approximately 5-10% of the cells became adipogenic as seen in Figure 5. Figure 5A shows hMSCs in culture which were not treated with either adipogenic medium but which were cultured, fixed and stained at the same time as the adipogenic cultures shown in 5B and 5C. Figure 5B was treated once with Adipogenic Induction Media and then cultured in Adipogenic Maintenance Media for an additional three weeks and then fixed in neutral buffered formalin and stained with Oil Red 0, a lipid soluble dye that accumulates in the fat droplets. A dish of hMSCs was also retreated with fresh Adipogenic Induction Media for a second and third 48 hour period to induce more hMSCs to become adipogenic as shown in Figure 5C. As many as 30-40% of the cells were converted to adipocytes by the three induction treatments when viewed two weeks after the third treatment. Panels 5A-5C were all stained with Oil Red O.
Expression of adipogenic proteins in differentiating hMSCs.
hMSCs express adipocyte-specific proteins following differentiation. In Figures 5D and 5E, lOg of total protein lysate was resolved by SDS-PAGE, transferred to nitrocellulose and probed with antibodies for C/EPBa or aP2. In Figure 5D, the transcription factor CAAT/enhancer binding protein (or C/EPBa) is expressed at high levels in the adipogenic hMSCs as shown by this western blot using an antibody specific for the 34 kd a isoform of C/EBP. In Figure 5E, the fatty acid binding protein aP2 shows high levels of expression in the adipogenic hMSCs as shown by this western blot using an antibody specific for the 14 kd adipocyte specific form of P2.
Expression of adipogenic genes in differentiating hMSCs The expression of transcription factors that are known to be involved in adipogenic differentiation also indicates that hMSCs have become adipocytes. A
class of compounds known as peroxisome proliferators, which includes some clinically used hypolipdemic agents, can activate nuclear receptors associated with adipogenic differentiation. The peroxisome proliferator activated receptor y2 (or PPARy2), in particular, has been shown to be associated with adipogenesis. RNA blot analysis (Northern blotting) was used to identify the elevated expression of PPAR y2 RNA in hMSCs undergoing adipogenic differentiation. Total RNA was isolated from control hMSCs and adipogenic hMSCs, resolved by denaturing gel electrophoresis and transferred to nitrocellulose and probed for the expression of PPARy2 cultures hMSCs (lane 1, 10 g) or adipogenic hMSCs (lane 2, 10 g; lane 3, 20 g). As shown in Figure 5F, the PPARy2 mRNA is detected at 1.7 kb as indicated by the arrow and its expression is elevated about 5 fold in RNA from the adipogenic hMSCs.
The elevated expression of RNA for lipoprotein lipase, an enzyme responsible for hydrolysis of the tryglyceride core to monoacylglycerol and free fatty acids, indicates adipogenic differentiation of hMSCs, as shown in Figure 5G. As in 5F, 10 g of total RNA from control hMSCs (lane 1) or adipogenic hMSCs (lane 2) or 20 g of RNA from adipogenic hMSCs was resolved by denaturing gel electrophoresis, transferred to nitrocellulose and probed for the expression of LPL RNA. The mRNA
for LPL is found as two bands of 3.3 and 3.7 kb lanes 2 and 3 (the bands in 3 are slightly shifted up due to the high loading).
r Example Isolation of Adipocvtes from hMSCs The generation of adipocytes from human mesenchymal stem cells by the conditions described above produces large numbers of adipocytes, perhaps as many as 30%-40% of the cells present. For uses requiring a pure population, the adipocytes can be isolated from the non-adipogenic hMSCs by several methods as listed below.
Method one for isolating adipogenic hMSCs uses density gradient centrifugation and takes advantage of the greater buoyancy of the lipid-containing adipogenic cells.
In this method, cultures containing hMSCs and adipocytes derived from hMSCs are treated with 0.05% trypsin/0.53 mM EDTA to remove the cells from the culture dish and the cells are washed by adding 10 ml of normal hMSC media and centrifuged for minutes at 1000 rpm in the GS-6R centrifuge (Beckman Instruments, Inc.) at 20 C.
The pelleted cells containing adipocytes and hMSCs are resuspended in 2 ml of the Adipogenic Maintenance Media and carefully layered on top of 8 ml of Percoll of a density of 1.045 g/ml. The tubes are centrifuged at 2,200 rpm (1100 xg) in a Beckman GS-6R centrifuge for 20 minutes at 3 C. The adipocytes are recovered in the uppermost 2 mis and at the interface with the 1.045 density Percoll. (The non-adipogenic MSCs enter into the 1.045 density Percoll and can be recovered at the bottom of the tube.) The recovered adipocytes are washed by addition of 10 mIs of the Adipogenic Maintenance Media and centrifuged at 1000 rpm for 10 min at 20 C in the GS-6R centrifuge.
The adipocytes are replaced at a density of 150,000 cells per 35 mm dish in Adipogenic Maintenance Media and returned to the incubator.
Method two for isolating adipogenic hMSCs uses fluorescence activated cell sorting (FACS). The hMSCs differentiating into adipocytes in a culture can be isolated by using a lipid soluble fluorescent dye, such as Nile Red (10-100 ug/ml) to stain lipid vacuole-containing adipocytes. The culture is then treated with trypsin/EDTA
as above to release the cells from the culture vessel and subjecting the mixed population to fluorescence activated cell sorting (FACS). The parameters on the machine are adjusted *Trade-mark to select and recover adipogenic cells in the population and they can be used directly or replated and cultured in the incubator.
As described below, Method three of isolating the adipogenic cells in a mixed population is to trypsin/EDTA treat and wash the cells as above. The cells are then placed in a tissue culture flask and the flask is filled with media. The flask is closed tightly and turned upside-down so that the surface treated for cell adhesion is uppermost.
The buoyant, lipid-droplet-containing adipocytes rise to top and attach to the surface of the flask. The next day the media is removed and the flask rinsed with fresh media and the flask turned right-side-up. The flask, now with only enough media to cover the cell layer, is returned to the incubator for further maintenance.
Adipogenic hMSCs accumulate lipid droplets which decreases the bouyant density of the cells. The adipogenic hMSCs were then isolated as follows. The dish of cells containing adipocytes and non-adipogenic hMSCs from a culture that were treated for only one 48 hr induction period and then grown for three weeks, was treated with 0.05 % trypsin and 5 mM EDTA for 3-5 minutes to release the cells from the dish. The cells were then rinsed from the dish with 10 ml of fresh media and placed in a 25 cm2 flask and the flask was filled to the brim with fresh media. The flask was turned upside down so the usual culture surface was uppermost and the flask placed in the 37 C
incubator overnight. The more bouyant adipogenic cells rose to the top and attached to the surface, while the non-adipogenic hMSCs settled to the bottom surface and attached.
The following day photos were taken of the cells on each surface as shown in Figure 6. Figure 6A shows the adipogenic hMSCs that attached to the uppermost surface. The population is composed of greater than 99 % adipogenic cells as evidenced by the lipid droplets in every cell. Figure 6B shows the non-adipogenic hMSCs that settled to the lower surface of the flask. Very few cells containing lipid droplets were present on the lower surface. These non-adipogenic cells could be treated with trypsin/EDTA
and replated to another dish and be shown to retain adipogenic potential (data not shown), indicating that they remain as mesenchymal stem cells, capable of lineage progression.
Method one for isolating adipogenic hMSCs uses density gradient centrifugation and takes advantage of the greater buoyancy of the lipid-containing adipogenic cells.
In this method, cultures containing hMSCs and adipocytes derived from hMSCs are treated with 0.05% trypsin/0.53 mM EDTA to remove the cells from the culture dish and the cells are washed by adding 10 ml of normal hMSC media and centrifuged for minutes at 1000 rpm in the GS-6R centrifuge (Beckman Instruments, Inc.) at 20 C.
The pelleted cells containing adipocytes and hMSCs are resuspended in 2 ml of the Adipogenic Maintenance Media and carefully layered on top of 8 ml of Percoll of a density of 1.045 g/ml. The tubes are centrifuged at 2,200 rpm (1100 xg) in a Beckman GS-6R centrifuge for 20 minutes at 3 C. The adipocytes are recovered in the uppermost 2 mis and at the interface with the 1.045 density Percoll. (The non-adipogenic MSCs enter into the 1.045 density Percoll and can be recovered at the bottom of the tube.) The recovered adipocytes are washed by addition of 10 mIs of the Adipogenic Maintenance Media and centrifuged at 1000 rpm for 10 min at 20 C in the GS-6R centrifuge.
The adipocytes are replaced at a density of 150,000 cells per 35 mm dish in Adipogenic Maintenance Media and returned to the incubator.
Method two for isolating adipogenic hMSCs uses fluorescence activated cell sorting (FACS). The hMSCs differentiating into adipocytes in a culture can be isolated by using a lipid soluble fluorescent dye, such as Nile Red (10-100 ug/ml) to stain lipid vacuole-containing adipocytes. The culture is then treated with trypsin/EDTA
as above to release the cells from the culture vessel and subjecting the mixed population to fluorescence activated cell sorting (FACS). The parameters on the machine are adjusted *Trade-mark to select and recover adipogenic cells in the population and they can be used directly or replated and cultured in the incubator.
As described below, Method three of isolating the adipogenic cells in a mixed population is to trypsin/EDTA treat and wash the cells as above. The cells are then placed in a tissue culture flask and the flask is filled with media. The flask is closed tightly and turned upside-down so that the surface treated for cell adhesion is uppermost.
The buoyant, lipid-droplet-containing adipocytes rise to top and attach to the surface of the flask. The next day the media is removed and the flask rinsed with fresh media and the flask turned right-side-up. The flask, now with only enough media to cover the cell layer, is returned to the incubator for further maintenance.
Adipogenic hMSCs accumulate lipid droplets which decreases the bouyant density of the cells. The adipogenic hMSCs were then isolated as follows. The dish of cells containing adipocytes and non-adipogenic hMSCs from a culture that were treated for only one 48 hr induction period and then grown for three weeks, was treated with 0.05 % trypsin and 5 mM EDTA for 3-5 minutes to release the cells from the dish. The cells were then rinsed from the dish with 10 ml of fresh media and placed in a 25 cm2 flask and the flask was filled to the brim with fresh media. The flask was turned upside down so the usual culture surface was uppermost and the flask placed in the 37 C
incubator overnight. The more bouyant adipogenic cells rose to the top and attached to the surface, while the non-adipogenic hMSCs settled to the bottom surface and attached.
The following day photos were taken of the cells on each surface as shown in Figure 6. Figure 6A shows the adipogenic hMSCs that attached to the uppermost surface. The population is composed of greater than 99 % adipogenic cells as evidenced by the lipid droplets in every cell. Figure 6B shows the non-adipogenic hMSCs that settled to the lower surface of the flask. Very few cells containing lipid droplets were present on the lower surface. These non-adipogenic cells could be treated with trypsin/EDTA
and replated to another dish and be shown to retain adipogenic potential (data not shown), indicating that they remain as mesenchymal stem cells, capable of lineage progression.
T
Example 4 Adino2enic MSCs in Reconstructive Surgery Adipocytes can be used with a variety of materials to form a composition for specific purposes such as reconstructive surgery. MSCs can be combined with a biomatrix to form a two dimensional or three dimensional material as needed.
Surgeons routinely use fat pads and fatty tissues from remote sites to build up an area where tissue has been removed. This often involves a separate procedure with its inherent risks. As an alternative, hMSCs are isolated from the patient and grown in culture.
The hMSCs are then mixed with biocompatible material such as collagen, collagen sponge, alginate, polylactic acid material etc. to form a composite. The composite is then treated to induce adipogenic differentiation of the MSCs in vitro for 1-3 weeks, then implanted when needed. For example, adipogenic MSCs are mixed with solubilized collagen or other biomaterial which is then allowed to gel to form a three dimensional composite that is useful for breast augmentation following masectomy.
Such a composite is formed or sculpted to the appropriate size and shape.
Figure 7 shows an example of hMSCs grown in stabilized collagen gel matrix and then induced to differentiate into adipocytes. The cells have been stained with Nile Red fluorescent dye that accumulates in the lipid vacuoles which are visualized by ultraviolet illumination. Only the lipid deposits in the cells are visible and many of the adipocytes are out of the plane of focus in the three dimensional matrix.
Another composition includes the culturing of hMSCs on accellular skin matrices that are currently on the market. In this format the cells are cultured to populate the matrix and then caused to differentiate as described. The matrix with the adipogenic cells is then cut by the surgeon to fit the site of reconstruction. As an alternative hMSCs can be induced to become adipocytes prior to their introduction into the biocompatible materials. Similar to their use in reconstructive surgery, adipogenic hMSCs are of use in elective cosmetic surgery in much the same way; to build up underlying tissue below the skin with a composite of autologous cells and biocompatible material.
Example 4 Adino2enic MSCs in Reconstructive Surgery Adipocytes can be used with a variety of materials to form a composition for specific purposes such as reconstructive surgery. MSCs can be combined with a biomatrix to form a two dimensional or three dimensional material as needed.
Surgeons routinely use fat pads and fatty tissues from remote sites to build up an area where tissue has been removed. This often involves a separate procedure with its inherent risks. As an alternative, hMSCs are isolated from the patient and grown in culture.
The hMSCs are then mixed with biocompatible material such as collagen, collagen sponge, alginate, polylactic acid material etc. to form a composite. The composite is then treated to induce adipogenic differentiation of the MSCs in vitro for 1-3 weeks, then implanted when needed. For example, adipogenic MSCs are mixed with solubilized collagen or other biomaterial which is then allowed to gel to form a three dimensional composite that is useful for breast augmentation following masectomy.
Such a composite is formed or sculpted to the appropriate size and shape.
Figure 7 shows an example of hMSCs grown in stabilized collagen gel matrix and then induced to differentiate into adipocytes. The cells have been stained with Nile Red fluorescent dye that accumulates in the lipid vacuoles which are visualized by ultraviolet illumination. Only the lipid deposits in the cells are visible and many of the adipocytes are out of the plane of focus in the three dimensional matrix.
Another composition includes the culturing of hMSCs on accellular skin matrices that are currently on the market. In this format the cells are cultured to populate the matrix and then caused to differentiate as described. The matrix with the adipogenic cells is then cut by the surgeon to fit the site of reconstruction. As an alternative hMSCs can be induced to become adipocytes prior to their introduction into the biocompatible materials. Similar to their use in reconstructive surgery, adipogenic hMSCs are of use in elective cosmetic surgery in much the same way; to build up underlying tissue below the skin with a composite of autologous cells and biocompatible material.
Example 5 Use Of AdiQogenic hMSCs As A Source Of Leptin As An Implant For Infertility The role of leptin in obesity also brings to mind questions about its role in women who have low body fat content and an irregular menstrual cycle, and who often cannot become pregnant. Recent research suggests leptin may serve as a metabolic regulator to signal when the body has sufficient fat stores to support conception and development of the fetus (Chebab et al. 1996) To the extent that adipogenic hMSCs are a good source of leptin, they can be used as an implant for the release of leptin to the body of such women. Such an implant can take the form of encapsulated adipogenic hMSCs or a matrix containing adipogenic hMSCs that can be implanted where the secreted products will have access to the circulatory system.
r Further details relating to adipogenic differentiation and relevant assays can be found in the following references:
MacDougald, O.A., C-S. Hwang, H. Fan, and M.D. Lane. 1995. Regulated expression of the obese gene product (leptin) in white adipose tissue and 3T3-adipocytes. PNAS 92:9034-9037.
Hwang, C-S., S. Mandrup, O.A. MacDougald, D.E. Geiman and M.D. Lane. 1996.
Transcriptional activation of the mouse obese (ob) gene by CCAAT/enhancer binding protein a. PNAS 93:873-877.
Cornelius, P., O.A. MacDougald and M.D. Lane. 1994. Regulation of adipocyte development. Annu. Rev. Nutrition 14:99-129.
Yeh, W-C., Z. Cao, M. Classon and S.L. McKnight. 1995. Cascade regulation of terminal adipocyte differentiation by three members of the C/EBP family of leucine zipper proteins. Genes and Development 9:168-181.
Freytag, S.O., and T.J. Geddes. 1992. Reciprocal regulation of adipogenesis by Myc and C/EBPa:. Science 29 :379-382.
Bortell, R., T.A. Owen, R. Ignotz, G.S. Stein and J.L. Stein. 1994. TGFO, prevents the down-regulation of type I procollagen, fibronectin, and TGFO, gene expression associated with 3T3-LI pre-adipocyte differentiation. J. Cellular Biochem.
X4:256-263.
Sadowski, H.B., T.T. Wheeler and D.A. Young. 1992. Gene expression during 3T3-L1 adipocyte differentiation. J. Biological Chem. 266:4722-4731.
Flier, S. J. 1995. The adipocyte:storage depot or node o the energy information superhighway. Cell 80:15-18.
MacDougald, O.A., C-S. Hwang, H. Fan, and M.D. Lane. 1995. Regulated expression of the obese gene product (leptin) in white adipose tissue and 3T3-adipocytes. PNAS 92:9034-9037.
Hwang, C-S., S. Mandrup, O.A. MacDougald, D.E. Geiman and M.D. Lane. 1996.
Transcriptional activation of the mouse obese (ob) gene by CCAAT/enhancer binding protein a. PNAS 93:873-877.
Cornelius, P., O.A. MacDougald and M.D. Lane. 1994. Regulation of adipocyte development. Annu. Rev. Nutrition 14:99-129.
Yeh, W-C., Z. Cao, M. Classon and S.L. McKnight. 1995. Cascade regulation of terminal adipocyte differentiation by three members of the C/EBP family of leucine zipper proteins. Genes and Development 9:168-181.
Freytag, S.O., and T.J. Geddes. 1992. Reciprocal regulation of adipogenesis by Myc and C/EBPa:. Science 29 :379-382.
Bortell, R., T.A. Owen, R. Ignotz, G.S. Stein and J.L. Stein. 1994. TGFO, prevents the down-regulation of type I procollagen, fibronectin, and TGFO, gene expression associated with 3T3-LI pre-adipocyte differentiation. J. Cellular Biochem.
X4:256-263.
Sadowski, H.B., T.T. Wheeler and D.A. Young. 1992. Gene expression during 3T3-L1 adipocyte differentiation. J. Biological Chem. 266:4722-4731.
Flier, S. J. 1995. The adipocyte:storage depot or node o the energy information superhighway. Cell 80:15-18.
Greenspan, P., E.P. Mayer and S.D. Fowler. 1985. Nile red: A selective fluorescent stain for intracellular lipid droplets. J. Cell Biology 100: 965-973.
Smith, M.J. and W. Wharton. 1992. Differentiation of A31T6 proadipocytes to adipocytes: A flow cytometric analysis. Exper. Cell Research 199:29-38.
Gimble, J.M., K. Youkhana, X. Hua, H. Bass, K. Medina. 1992. Adipogenesis in a myeloid supporting bone marrow stroma cell line. J. Cell. Biochem. 50:73-82.
Pietrangell, C.E., S-1. Hayashi and P.W. Kincade. 1988. Stromal cell lines which support lymphocyte growth: characterization, sensitivity to radiation and responsiveness to growth factors, Europ. J. Immunolgy. 18:863-872.
Chehab, F.F., M. E. Lim and R. Lu. 1996. Correction of the sterility defect in homozygous obese female mice by treatment with the human recombinant leptin.
Nature Genetics 12 318-320.
Beresford, J.N., J.H. Bennett, C. Devlin, P.S. Leboy and M.E. Owen. 1992.
Evidence for an inverse relationship between the differentiation of adipocytic and osteogenic cells in rat marrow stromal cell cultures. J. Cell Science 102:341-351.
Bortell, R. T.A. Owen, R. Ignotz, G.S. Stein and J.L. Stein. 1994. TGF 0, prevents the down regulation of type I procollagen, fibrinectin, and TGF (31 geneexpression associated with 3T3-L1 pre-adipocvte differentiation. J. Cellular Biochem.
54:256-263.
Gimble, J.M., C. Morgan, K.Kelly, X.Wu, V.Dandapani, C.-S. Wang and V. Rosen.
1995. Bone Morphogenetic Proteins inhibit adipogenic differentiation by bone marrow stromal cells. J. Cellular Biochemistry 58:393-402.
Smith, M.J. and W. Wharton. 1992. Differentiation of A31T6 proadipocytes to adipocytes: A flow cytometric analysis. Exper. Cell Research 199:29-38.
Gimble, J.M., K. Youkhana, X. Hua, H. Bass, K. Medina. 1992. Adipogenesis in a myeloid supporting bone marrow stroma cell line. J. Cell. Biochem. 50:73-82.
Pietrangell, C.E., S-1. Hayashi and P.W. Kincade. 1988. Stromal cell lines which support lymphocyte growth: characterization, sensitivity to radiation and responsiveness to growth factors, Europ. J. Immunolgy. 18:863-872.
Chehab, F.F., M. E. Lim and R. Lu. 1996. Correction of the sterility defect in homozygous obese female mice by treatment with the human recombinant leptin.
Nature Genetics 12 318-320.
Beresford, J.N., J.H. Bennett, C. Devlin, P.S. Leboy and M.E. Owen. 1992.
Evidence for an inverse relationship between the differentiation of adipocytic and osteogenic cells in rat marrow stromal cell cultures. J. Cell Science 102:341-351.
Bortell, R. T.A. Owen, R. Ignotz, G.S. Stein and J.L. Stein. 1994. TGF 0, prevents the down regulation of type I procollagen, fibrinectin, and TGF (31 geneexpression associated with 3T3-L1 pre-adipocvte differentiation. J. Cellular Biochem.
54:256-263.
Gimble, J.M., C. Morgan, K.Kelly, X.Wu, V.Dandapani, C.-S. Wang and V. Rosen.
1995. Bone Morphogenetic Proteins inhibit adipogenic differentiation by bone marrow stromal cells. J. Cellular Biochemistry 58:393-402.
Grigoriadis, A.E., J.N.M.Heersche and J.E. Aubin. 1988. Differentiation of muscle, fat, cartilagem and bone from progenitor cells present in a bone derived clonal cell population: effect of dexamethasone. J. Cell Biology 106:2139-2151.
Ibid., 1990. Continuosly growing bipotential and monopotential myogenic adipogenic and chondrogenic subclones isolated from the multipotential RCJ 3.1 clonal cell line.
Developmental Biology 142:313-318.
Umezawa, A., K.Tachlbana, K. Harigaya, S. Kusakarl, S. Kato, Y. Watanabe and T.Takano. 1991. Colony stimulating factor I expression is down-regulated during the adipocyte differentiation of H-1/A marrow stromal cells and induced by cachetin/tumor necrosis factor. Mol. Cell. Biol. 11:920-927.
Yamaguchi, A. and A.J. Kahn. 1991. Clonal osteogenic cell lines express myogenic and adipocytic developmental potential. Calcified Tissue International 49: 221-225.
Cheneval, D.R. J. Christy, D.Geiman, P.Cornelius, and M.D. Lane, 1991. Cell-free transcription directed by the 422 adipose P2 gene promoter: activation by the CCAAT/enhancer bindind protein. Proc. National Academy of Sciences USA 88:8465-69.
Ingalls, A.M., M.M. Dickie and G.D. Snell. 1950, Obese, a new mutation in the house mouse, J. Heredity 41:371-318.
Tontonoz, P.E., Hu, and B.M. Spiegelman. 1994. Stimulation of adipogenesis in fibroblasts by mPPARy2, a lipid activated transcription factor. Cell 79:1147-1156.
Konieczny, S.F. and C.P. Emerson. 1984. 5-azacytidine induction of stable mesodermal stem cell lineages from 10T1/2 cells: evidence for regulatory genes controlling differentiation. Cell 38:791-800.
Ibid., 1990. Continuosly growing bipotential and monopotential myogenic adipogenic and chondrogenic subclones isolated from the multipotential RCJ 3.1 clonal cell line.
Developmental Biology 142:313-318.
Umezawa, A., K.Tachlbana, K. Harigaya, S. Kusakarl, S. Kato, Y. Watanabe and T.Takano. 1991. Colony stimulating factor I expression is down-regulated during the adipocyte differentiation of H-1/A marrow stromal cells and induced by cachetin/tumor necrosis factor. Mol. Cell. Biol. 11:920-927.
Yamaguchi, A. and A.J. Kahn. 1991. Clonal osteogenic cell lines express myogenic and adipocytic developmental potential. Calcified Tissue International 49: 221-225.
Cheneval, D.R. J. Christy, D.Geiman, P.Cornelius, and M.D. Lane, 1991. Cell-free transcription directed by the 422 adipose P2 gene promoter: activation by the CCAAT/enhancer bindind protein. Proc. National Academy of Sciences USA 88:8465-69.
Ingalls, A.M., M.M. Dickie and G.D. Snell. 1950, Obese, a new mutation in the house mouse, J. Heredity 41:371-318.
Tontonoz, P.E., Hu, and B.M. Spiegelman. 1994. Stimulation of adipogenesis in fibroblasts by mPPARy2, a lipid activated transcription factor. Cell 79:1147-1156.
Konieczny, S.F. and C.P. Emerson. 1984. 5-azacytidine induction of stable mesodermal stem cell lineages from 10T1/2 cells: evidence for regulatory genes controlling differentiation. Cell 38:791-800.
Spiegelman, B.M. and H. Green. 1980. Control of specific protein biosynthesis during the adipose conversion of 3T3 cells. J. Biol. Chem. 255:8811-8818.
Zhang, Y. et al. 1994. Nature 372:425-432.
MacDougald. O.A. and M.D. Lane 1995. Transcriptional Regulation of gene expression during adipocyte differentiation. Annu. Rev. Biochem. 64:345-373.
Chehab, F.F., M. E. Lim and R. Lu. 1996. Correction of the sterility defect in homozygous obese female mice by treatment with the human recombinant leptin.
Nature Genetics 12:318-320.
Zhang, Y. et al. 1994. Nature 372:425-432.
MacDougald. O.A. and M.D. Lane 1995. Transcriptional Regulation of gene expression during adipocyte differentiation. Annu. Rev. Biochem. 64:345-373.
Chehab, F.F., M. E. Lim and R. Lu. 1996. Correction of the sterility defect in homozygous obese female mice by treatment with the human recombinant leptin.
Nature Genetics 12:318-320.
Claims (26)
1. A composition which comprises mesenchymal stem cells which have been isolated from a human and which have potential to differentiate into cells of more than one connective tissue type and a substance in an amount effective to induce said stem cells to differentiate into adipogenic lineage cells, wherein the substance which induces said stem cells to differentiate into the adipogenic lineage cells comprises a glucocorticoid and a compound which elevates intracellular levels of cAMP.
2. The composition of claim 1 wherein the glucocorticoid is selected from the group consisting of dexamethasone, hydrocortisone, and cortisone.
3. The composition of claim 1 or 2 wherein the compound which elevates intracellular cAMP is selected from the group consisting of dibutyryl-cAMP, 8-CPT-cAMP (8-(4) chloro-phenyl-thio)-adenosine 3', 5' cyclic monophosphate;
8-bromo-cAMP; dioctanoyl-cAMP and Forskolin.
8-bromo-cAMP; dioctanoyl-cAMP and Forskolin.
4. The composition of any one of claims 1 to 3 wherein the substance which induces cells from the mesenchymal stem cell population to differentiate into the adipogenic lineage cells further comprises insulin.
5. A process for inducing human mesenchymal stem cells (hMSCs) ex vivo to differentiate into adipocytes, comprising:
contacting human mesenchymal stem cells with (i) a glucocorticoid and (ii) a compound which elevates intracellular levels of cAMP, said glucocorticoid and said compound which elevates intracellular levels of cAMP being employed in an amount sufficient to induce human mesenchymal stem cells to differentiate into adipocytes.
contacting human mesenchymal stem cells with (i) a glucocorticoid and (ii) a compound which elevates intracellular levels of cAMP, said glucocorticoid and said compound which elevates intracellular levels of cAMP being employed in an amount sufficient to induce human mesenchymal stem cells to differentiate into adipocytes.
6. A process for inducing human mesenchymal stem cells ex vivo to differentiate into adipocytes, comprising:
contacting human mesenchymal stem cells with (i) a glucocorticoid and (ii) a compound which inhibits degradation of cAMP, said glucocorticoid and said compound which inhibits degradation of cAMP being employed in an amount sufficient to induce human mesenchymal stem cells to differentiate into adipocytes.
contacting human mesenchymal stem cells with (i) a glucocorticoid and (ii) a compound which inhibits degradation of cAMP, said glucocorticoid and said compound which inhibits degradation of cAMP being employed in an amount sufficient to induce human mesenchymal stem cells to differentiate into adipocytes.
7. The process of claim 5 or 6 which further comprises isolating the adipocytes from remaining hMSCs.
8. The process of any one of claims 5 to 7 wherein (ii) is a phosphodiesterase inhibitor.
9. The process of any one of claims 5 to 8 wherein (i) and (ii) are in admixture with each other.
10. The composition of claim 1 or 2 wherein the substance which induces cells from the mesenchymal stem cell population to differentiate into adipogenic lineage cells comprises a glucocorticoid and a compound which inhibits degradation of cAMP.
11. The composition of claim 10 wherein the compound which inhibits degradation of cAMP is a phosphodiesterase inhibitor selected from the group consisting of methyl isobutylxanthine, theophylline, caffeine, and indomethacin.
12. The composition of claim 10 or 11 wherein the substance which induces cells from the mesenchymal stem cell population to differentiate into adipogenic lineage cells further comprises insulin.
13. A composition for producing adipocytes, comprising isolated human mesenchymal stem cells in a biocompatible matrix which supports the differentiation and maturation of human mesenchymal stem cells into adipocytes and a substance in an amount effective to induce said stem cells to differentiate into adipocytes, wherein the substance which induces said stem cells to differentiate into the adipogenic lineage cells comprises a glucocorticoid and a compound which elevates intracellular levels of cAMP.
14. The composition of claim 13, wherein the matrix is comprised of collagen or alginate.
15. The composition of claim 13 or 14 wherein the glucocorticoid is selected from the group consisting of dexamethasone, hydrocortisone, and cortisone.
16. The composition of any one of claims 13 to 15 wherein the compound which elevates intracellular cAMP is selected from the group consisting of dibutyryl-cAMP, 8-CPT-cAMP (8-(4) chloro-phenyl-thio)-adenosine 3', 5' cyclic monophosphate; 8-bromo-cAMP; dioctanoyl-cAMP and Forskolin.
17. The composition of any one of claims 13 to 16 wherein the substance which induces cells from the mesenchymal stem cell population to differentiate into the adipogenic lineage cells further comprises insulin.
18. The composition of any one of claims 13 to 16 wherein the substance which induces cells from the mesenchymal stem cell population to differentiate into adipogenic lineage cells comprises a glucocorticoid and a compound which inhibits degradation of cAMP.
19. The composition of claim 18 wherein the compound which inhibits degradation of cAMP is a phosphodiesterase inhibitor selected from the group consisting of methyl isobutylxanthine, theophylline, caffeine, and indomethacin.
20. The composition of claim 18 or 19 wherein the substance which induces cells from the mesenchymal stem cell population to differentiate into adipogenic lineage cells further comprises insulin.
21. Use of a glucocorticoid and a compound which elevates intracellular levels of a cAMP for inducing human mesenchymal stem cells (hMSCs) to differentiate into adipocytes.
22. Use for the manufacture of a medicament of a glucocorticoid and a compound which elevates intracellular levels of a cAMP for inducing human mesenchymal stem cells (hMSCs) to differentiate into adipocytes.
23. Use of a glucocorticoid and a compound which inhibits degradation of cAMP for inducing human mesenchymal stem cells (hMSCs) to differentiate into adipocytes.
24. Use of a glucocorticoid and a compound which inhibits degradation of cAMP for the manufacture of a medicament for inducing human mesenchymal stem cells (hMSCs) to differentiate into adipocytes.
25. The use according to any one of claims 21 to 24 wherein said compound is a phosphodiesterase inhibitor.
26. The use according to any one of claims 21 to 25 wherein said glucocorticoid and said compound are in admixture with each other.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/700,753 US5827740A (en) | 1996-07-30 | 1996-07-30 | Adipogenic differentiation of human mesenchymal stem cells |
US08/700,753 | 1996-07-30 | ||
PCT/US1997/012356 WO1998004682A1 (en) | 1996-07-30 | 1997-07-21 | Adipogenic differentiation of human mesenchymal stem cells |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2262014A1 CA2262014A1 (en) | 1998-02-05 |
CA2262014C true CA2262014C (en) | 2010-09-14 |
Family
ID=24814738
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2262014A Expired - Fee Related CA2262014C (en) | 1996-07-30 | 1997-07-21 | Adipogenic differentiation of human mesenchymal stem cells |
Country Status (11)
Country | Link |
---|---|
US (3) | US5827740A (en) |
EP (2) | EP1659172A1 (en) |
JP (1) | JP2001523084A (en) |
AT (1) | ATE342349T1 (en) |
AU (1) | AU3729097A (en) |
CA (1) | CA2262014C (en) |
DE (1) | DE69736814T2 (en) |
DK (1) | DK0954565T3 (en) |
ES (1) | ES2274547T3 (en) |
PT (1) | PT954565E (en) |
WO (1) | WO1998004682A1 (en) |
Families Citing this family (184)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5827740A (en) * | 1996-07-30 | 1998-10-27 | Osiris Therapeutics, Inc. | Adipogenic differentiation of human mesenchymal stem cells |
KR20000076007A (en) * | 1997-03-07 | 2000-12-26 | 나가야마 오사무 | Novel cell line and screening method with the use of the same |
US6153432A (en) * | 1999-01-29 | 2000-11-28 | Zen-Bio, Inc | Methods for the differentiation of human preadipocytes into adipocytes |
US6777231B1 (en) * | 1999-03-10 | 2004-08-17 | The Regents Of The University Of California | Adipose-derived stem cells and lattices |
KR100968165B1 (en) * | 1999-03-10 | 2010-07-06 | 더 리전츠 오브 더 유니버시티 오브 캘리포니아 | Adipose-derived stem cells and lattices |
US20030082152A1 (en) * | 1999-03-10 | 2003-05-01 | Hedrick Marc H. | Adipose-derived stem cells and lattices |
US20050076396A1 (en) * | 1999-03-10 | 2005-04-07 | Katz Adam J. | Adipose-derived stem cells and lattices |
AU2003901668A0 (en) * | 2003-03-28 | 2003-05-01 | Medvet Science Pty. Ltd. | Non-haemopoietic precursor cells |
US8062675B2 (en) * | 1999-07-07 | 2011-11-22 | Angioblast Systems, Inc. | Mesenchymal precursor cell |
US7670628B2 (en) * | 1999-07-07 | 2010-03-02 | Angioblast Systems, Inc. | Mesenchymal precursor cell |
AUPQ147799A0 (en) * | 1999-07-07 | 1999-07-29 | Medvet Science Pty. Ltd. | Mesenchymal precursor cell |
US20050158289A1 (en) * | 1999-07-07 | 2005-07-21 | Simmons Paul J. | Mesenchymal precursor cell and use thereof in the repair of bone defects and fractures in mammals |
IL147990A0 (en) | 1999-08-05 | 2002-09-12 | Mcl Llc | Multipotent adult stem cells and methods for isolation |
JP2003517858A (en) * | 1999-11-05 | 2003-06-03 | ジェリジーン メディカル コーポレーション | Augmentation and repair of age-related soft tissue defects |
AU3081801A (en) * | 1999-11-15 | 2001-05-30 | Chemclean Corporation | Bio-burden visualization system |
DK1290444T3 (en) | 2000-06-14 | 2010-01-18 | Vistagen Inc | Toxicity typing using liver stem cells |
EP1303589B1 (en) * | 2000-07-18 | 2007-09-12 | Société des Produits Nestlé S.A. | Pre-adipose cell lines |
US20030032179A1 (en) | 2000-12-06 | 2003-02-13 | Hariri Robert J. | Post-partum mammalian placenta, its use and placental stem cells therefrom |
AU2002220209B2 (en) | 2000-12-06 | 2006-05-25 | Robert J. Hariri | Method of collecting placental stem cells |
US7311905B2 (en) | 2002-02-13 | 2007-12-25 | Anthrogenesis Corporation | Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells |
US20080152629A1 (en) * | 2000-12-06 | 2008-06-26 | James Edinger | Placental stem cell populations |
US6869766B2 (en) * | 2000-12-22 | 2005-03-22 | The Regents Of The University Of California | Gene associated with regulation of adiposity and insulin response |
KR101012952B1 (en) * | 2001-02-14 | 2011-02-08 | 안트로제네시스 코포레이션 | Post-partum mammalian placenta, its use and placental stem cells therefrom |
EP1921133B1 (en) | 2001-12-07 | 2015-05-20 | Cytori Therapeutics, Inc. | System for processing lipoaspirate cells |
US7771716B2 (en) | 2001-12-07 | 2010-08-10 | Cytori Therapeutics, Inc. | Methods of using regenerative cells in the treatment of musculoskeletal disorders |
US8105580B2 (en) | 2001-12-07 | 2012-01-31 | Cytori Therapeutics, Inc. | Methods of using adipose derived stem cells to promote wound healing |
US20050048036A1 (en) * | 2001-12-07 | 2005-03-03 | Hedrick Marc H. | Methods of using regenerative cells in the treatment of inherited and acquired disorders of the bone, bone marrow, liver, and other tissues |
US9597395B2 (en) | 2001-12-07 | 2017-03-21 | Cytori Therapeutics, Inc. | Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions |
US20050008626A1 (en) * | 2001-12-07 | 2005-01-13 | Fraser John K. | Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions |
US7595043B2 (en) * | 2001-12-07 | 2009-09-29 | Cytori Therapeutics, Inc. | Method for processing and using adipose-derived stem cells |
US20060204556A1 (en) * | 2001-12-07 | 2006-09-14 | Cytori Therapeutics, Inc. | Cell-loaded prostheses for regenerative intraluminal applications |
US7651684B2 (en) * | 2001-12-07 | 2010-01-26 | Cytori Therapeutics, Inc. | Methods of using adipose tissue-derived cells in augmenting autologous fat transfer |
US7585670B2 (en) | 2001-12-07 | 2009-09-08 | Cytori Therapeutics, Inc. | Automated methods for isolating and using clinically safe adipose derived regenerative cells |
US20050095228A1 (en) * | 2001-12-07 | 2005-05-05 | Fraser John K. | Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders |
US7514075B2 (en) * | 2001-12-07 | 2009-04-07 | Cytori Therapeutics, Inc. | Systems and methods for separating and concentrating adipose derived stem cells from tissue |
US8404229B2 (en) | 2001-12-07 | 2013-03-26 | Cytori Therapeutics, Inc. | Methods of using adipose derived stem cells to treat acute tubular necrosis |
WO2003053362A2 (en) * | 2001-12-20 | 2003-07-03 | Macropore, Inc. | Systems and methods for treating patients with collagen-rich material extracted from adipose tissue |
CA2471147C (en) * | 2002-01-04 | 2010-08-10 | Henry Ford Health System | Nitric oxide donors for treatment of disease and injury |
US20030220280A1 (en) * | 2002-02-07 | 2003-11-27 | Bunge Mary Bartlett | Schwann cell bridge implants and phosphodiesterase inhibitors to stimulate CNS nerve regeneration |
EP1487463A2 (en) * | 2002-03-02 | 2004-12-22 | Board Of Regents The University Of Texas System | Local production and/or delivery of anti-cancer agents by stromal cell precursors |
WO2003080801A2 (en) * | 2002-03-19 | 2003-10-02 | Advanced Research & Technology Transfer | Adipose stromal stem cells for tissue and vascular modification |
TWI288779B (en) * | 2002-03-28 | 2007-10-21 | Blasticon Biotech Forschung | Dedifferentiated, programmable stem cells of monocytic origin, and their production and use |
WO2003084468A2 (en) * | 2002-04-03 | 2003-10-16 | Artecel Sciences, Inc. | Improvements of adipocytic differentiated adipose derived adult stem cells and uses thereof |
US7060494B2 (en) * | 2002-04-09 | 2006-06-13 | Reliance Life Sciences Pvt. Ltd. | Growth of human Mesenchymal Stem Cells (hMSC) using umbilical cord blood serum and the method for the preparation thereof |
MXPA04009997A (en) * | 2002-04-12 | 2004-12-13 | Celgene Corp | Modulation of stem and progenitor cell differentiation, assays, and uses thereof. |
JP2005528105A (en) * | 2002-05-30 | 2005-09-22 | セルジーン・コーポレーション | Methods of using JNK or MKK inhibitors to modulate cell differentiation and to treat myeloproliferative diseases and myelodysplastic syndromes |
KR101042448B1 (en) * | 2002-11-26 | 2011-06-16 | 안트로제네시스 코포레이션 | Cytotherapeutics, cytotherapeutic units and methods for treatments using them |
NZ566132A (en) * | 2003-02-13 | 2009-09-25 | Anthrogenesis Corp | Use of umbilical cord blood to treat inflammation, ParkinsonÆs disease or diabetes |
KR100865884B1 (en) | 2003-03-18 | 2008-10-31 | (주)안트로젠 | Differentiated adipocyte for allogenic transplantation |
ATE482725T1 (en) * | 2003-04-01 | 2010-10-15 | Us Dept Of Veteran S Affaires | STEM CELL, PROGRESSOR CELL OR TARGET CELL BASED TREATMENT OF MULTI-ORGAN FAILURE. |
EP1702062A2 (en) * | 2003-06-11 | 2006-09-20 | Jan Remmereit | Differentiation of stem cells for therapeutic use |
US20050042595A1 (en) * | 2003-08-14 | 2005-02-24 | Martin Haas | Banking of multipotent amniotic fetal stem cells |
US7012273B2 (en) * | 2003-08-14 | 2006-03-14 | Silicon Storage Technology, Inc. | Phase change memory device employing thermal-electrical contacts with narrowing electrical current paths |
GB0321337D0 (en) * | 2003-09-11 | 2003-10-15 | Massone Mobile Advertising Sys | Method and system for distributing advertisements |
WO2005033297A1 (en) * | 2003-09-19 | 2005-04-14 | The Rockefeller University | Compositions, methods and kits relating to reprogramming adult differentiated cells and production of embryonic stem cell-like cells |
WO2005035742A2 (en) | 2003-10-08 | 2005-04-21 | Vet-Stem Inc. | Methods of preparing and using stem cell compositions and kits comprising the same |
WO2005079250A2 (en) * | 2004-02-13 | 2005-09-01 | Cornell Research Foundation, Inc. | Purines are self-renewal signals for neural stem cells, and purine receptor antagonists promote neuronal and glial differentiation therefrom |
CA2563518C (en) | 2004-04-23 | 2014-09-02 | Bioe, Inc. | Multi-lineage progenitor cells |
US7622108B2 (en) | 2004-04-23 | 2009-11-24 | Bioe, Inc. | Multi-lineage progenitor cells |
KR101598947B1 (en) | 2004-09-24 | 2016-03-08 | 메소블라스트, 아이엔씨. | Method of enhancing proliferation and/or survival of mesenchymal precursor cells (mpc) |
WO2006052991A2 (en) | 2004-11-11 | 2006-05-18 | The General Hosptial Corporation | Parathyroid hormone receptor activation and stem and progenitor cell expansion |
US20060134781A1 (en) * | 2004-12-07 | 2006-06-22 | Bacterin International, Inc. | Three-dimensional cell culture system |
CA2512667A1 (en) * | 2005-01-07 | 2006-07-07 | Takahiro Ochiya | Human hepatocyte-like cells and uses thereof |
EP1844434A4 (en) * | 2005-01-10 | 2013-11-13 | Cytori Therapeutics Inc | Devices and methods for monitoring, managing, and servicing medical devices |
EP1880002A4 (en) * | 2005-05-10 | 2009-03-11 | Us Health | Therapy of kidney diseases and multiorgan failure with mesenchymal stem cells and mesenchymal stem cell conditioned media |
JP2008545703A (en) | 2005-05-27 | 2008-12-18 | バイアセル インコーポレーティッド | Treatment of ischemia using stem cells |
US8568761B2 (en) * | 2005-07-15 | 2013-10-29 | Cormatrix Cardiovascular, Inc. | Compositions for regenerating defective or absent myocardium |
US7531355B2 (en) | 2005-07-29 | 2009-05-12 | The Regents Of The University Of California | Methods and compositions for smooth muscle reconstruction |
MX2008001709A (en) * | 2005-08-01 | 2008-11-26 | Nupotential Inc | Production of reprogrammed cells with restored potential. |
EP2796544B1 (en) | 2005-09-09 | 2019-04-03 | Duke University | Tissue engineering methods and compositions |
ES2452595T3 (en) | 2005-10-13 | 2014-04-02 | Anthrogenesis Corporation | Immunomodulation using placental stem cells |
US20080070303A1 (en) * | 2005-11-21 | 2008-03-20 | West Michael D | Methods to accelerate the isolation of novel cell strains from pluripotent stem cells and cells obtained thereby |
AU2006332679A1 (en) | 2005-12-29 | 2007-07-12 | Anthrogenesis Corporation | Co-culture of placental stem cells and stem cells from a second source |
KR20210122908A (en) | 2005-12-29 | 2021-10-12 | 안트로제네시스 코포레이션 | Placental stem cell populations |
US8592209B2 (en) * | 2006-01-30 | 2013-11-26 | University Of Virginia Patent Foundation | Methods of preparing and characterizing mesenchymal stem cell aggregates and uses thereof |
WO2007121443A2 (en) | 2006-04-17 | 2007-10-25 | Bioe, Inc. | Differentiation of multi-lineage progenitor cells to respiratory epithelial cells |
WO2007139551A1 (en) * | 2006-05-30 | 2007-12-06 | Cytori Therapeutics, Inc. | Systems and methods for manipulation of regenerative cells from adipose tissue |
CN101501185A (en) * | 2006-06-09 | 2009-08-05 | 人类起源公司 | Placental niche and use thereof to culture stem cells |
WO2008013863A2 (en) * | 2006-07-26 | 2008-01-31 | Cytori Therapeutics, Inc. | Generation of adipose tissue and adipocytes |
US7993918B2 (en) | 2006-08-04 | 2011-08-09 | Anthrogenesis Corporation | Tumor suppression using placental stem cells |
CA2665475A1 (en) * | 2006-10-06 | 2008-05-22 | University Of Virginia Patent Foundation | Methods and compositions useful for diabetic wound healing |
DK2084268T3 (en) | 2006-10-23 | 2019-01-21 | Celularity Inc | METHODS AND COMPOSITIONS FOR TREATING BONE JOIN DEFECTS WITH PLACENTACLE POPULATIONS |
TW200822930A (en) * | 2006-11-22 | 2008-06-01 | Chao-Song Hsue | Composition for reducing weight and curing hypertriglyceridemia, the effective ingredients thereof containing cyclic AMP, nicotinic acid, prostaglandin, gamma linolenic acid, and xanthine derivates |
EP2129775A1 (en) | 2007-02-12 | 2009-12-09 | Anthrogenesis Corporation | Hepatocytes and chondrocytes from adherent placental stem cells; and cd34+, cd45- placental stem cell-enriched cell populations |
DK2120977T3 (en) | 2007-02-12 | 2013-08-12 | Anthrogenesis Corp | Treatment of inflammatory diseases using placental stem cells |
US7632340B2 (en) * | 2007-03-07 | 2009-12-15 | Hamilton Beach Brands, Inc. | Air purifier for removing particles or contaminants from air |
EP2607477B1 (en) | 2007-05-03 | 2020-09-23 | The Brigham and Women's Hospital, Inc. | Multipotent stem cells and uses thereof |
US8574567B2 (en) * | 2007-05-03 | 2013-11-05 | The Brigham And Women's Hospital, Inc. | Multipotent stem cells and uses thereof |
TWM322542U (en) * | 2007-05-23 | 2007-11-21 | Universal Scient Ind Co Ltd | Testing machine |
CN101835479A (en) * | 2007-07-25 | 2010-09-15 | 佰欧益有限公司 | Differentiation of multi-lineage progenitor cells to chondrocytes |
US9200253B1 (en) | 2007-08-06 | 2015-12-01 | Anthrogenesis Corporation | Method of producing erythrocytes |
KR101644659B1 (en) * | 2007-09-26 | 2016-08-01 | 안트로제네시스 코포레이션 | Angiogenic cells from human placental perfusate |
KR20210022148A (en) | 2007-09-28 | 2021-03-02 | 안트로제네시스 코포레이션 | Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells |
KR20160040739A (en) * | 2007-11-07 | 2016-04-14 | 안트로제네시스 코포레이션 | Use of umbilical cord blood in the treatment of premature birth complications |
US20100278788A1 (en) * | 2008-01-11 | 2010-11-04 | Bone Therapeutics, S.A. | Osteogenic Differentiation Of Bone Marrow Stem Cells And Mesenchymal Stem Cells Using A Combination Of Growth Factors |
US20100189338A1 (en) * | 2008-04-09 | 2010-07-29 | Nexcelom Bioscience | Systems and methods for counting cells and biomolecules |
JP2011523357A (en) * | 2008-05-06 | 2011-08-11 | ジョスリン ダイアビーティス センター インコーポレイテッド | Methods and compositions for inducing brown adipocyte differentiation |
JP6097479B2 (en) | 2008-05-07 | 2017-03-15 | ボーン セラピューティクス エス.アー. | Novel mesenchymal stem cells and osteogenic cells |
EP2294187A2 (en) * | 2008-05-21 | 2011-03-16 | BioE LLC | Differentiation of multi-lineage progenitor cells to pancreatic cells |
NZ591146A (en) * | 2008-08-14 | 2012-10-26 | Osiris Therapeutics Inc | Composition comprising mesenchymal stem cell aggregates wherein the D90 of said aggregates is less than 150 micomills |
WO2010021993A1 (en) | 2008-08-19 | 2010-02-25 | Cytori Therapeutics, Inc. | Methods of using adipose tissue-derived cells in the treatment of the lymphatic system and malignant disease |
KR101903049B1 (en) | 2008-08-20 | 2018-11-07 | 안트로제네시스 코포레이션 | Treatment of stroke using isolated placental cells |
KR20110050521A (en) | 2008-08-20 | 2011-05-13 | 안트로제네시스 코포레이션 | Improved cell composition and methods of making the same |
KR20110050688A (en) | 2008-08-22 | 2011-05-16 | 안트로제네시스 코포레이션 | Methods and compositions for treatment of bone defects with placental cell populations |
EP2182055A1 (en) | 2008-10-14 | 2010-05-05 | Heinrich-Heine-Universität Düsseldorf | Human cord blood derived unrestricted somatic stem cells (USSC) |
US20100098739A1 (en) * | 2008-10-20 | 2010-04-22 | University Of Virginia Patent Foundation | Compositions and methods for modular soft tissue repair |
AU2009316541B2 (en) | 2008-11-19 | 2015-08-06 | Celularity Inc. | Amnion derived adherent cells |
US9192695B2 (en) | 2008-11-20 | 2015-11-24 | Allosource | Allografts combined with tissue derived stem cells for bone healing |
ES2731340T3 (en) * | 2008-11-21 | 2019-11-15 | Celularity Inc | Treatment of diseases, disorders or lung conditions using placental cells |
AU2010242780B2 (en) | 2009-05-01 | 2016-04-21 | Puregraft Llc | Systems, methods and compositions for optimizing tissue and cell enriched grafts |
US9301975B2 (en) | 2009-05-01 | 2016-04-05 | Biocardia, Inc. | Method of preparing autologous cells and method of use for therapy |
CA2767014C (en) | 2009-07-02 | 2022-01-25 | Anthrogenesis Corporation | Method of producing erythrocytes without feeder cells |
EP2456860B1 (en) | 2009-07-21 | 2018-09-05 | ABT Holding Company | Use of stem cells to reduce leukocyte extravasation |
AU2010276201B2 (en) | 2009-07-21 | 2013-10-17 | Abt Holding Company | Use of stem cells to reduce leukocyte extravasation |
KR20110038569A (en) * | 2009-10-08 | 2011-04-14 | 주식회사 알앤엘바이오 | Anti-tumor composition comprising a human-derived adult stem cells |
EP2489727A4 (en) * | 2009-10-08 | 2013-05-08 | Seoul Nat Univ Hospital | Method of inducing high activity of human adipose stem cell and medium therefor |
US9044606B2 (en) | 2010-01-22 | 2015-06-02 | Ethicon Endo-Surgery, Inc. | Methods and devices for activating brown adipose tissue using electrical energy |
US8476227B2 (en) | 2010-01-22 | 2013-07-02 | Ethicon Endo-Surgery, Inc. | Methods of activating a melanocortin-4 receptor pathway in obese subjects |
EP3284818B1 (en) | 2010-01-26 | 2022-03-09 | Celularity Inc. | Treatment of bone-related cancers using placental stem cells |
SG10201501402UA (en) | 2010-02-25 | 2015-04-29 | Abt Holding Co | Modulation of macrophage activation |
KR20230054905A (en) | 2010-04-07 | 2023-04-25 | 셀룰래리티 인코포레이티드 | Angiogenesis using placental stem cells |
WO2011127113A1 (en) | 2010-04-08 | 2011-10-13 | Anthrogenesis Corporation | Treatment of sarcoidosis using placental stem cells |
WO2011130402A2 (en) | 2010-04-13 | 2011-10-20 | Cellular Dynamics International, Inc. | Hepatocyte production by forward programming |
WO2011159797A2 (en) | 2010-06-15 | 2011-12-22 | Cellular Dynamics International, Inc. | A compendium of ready-built stem cell models for interrogation of biological response |
CA2804595C (en) | 2010-07-07 | 2018-11-13 | Cellular Dynamics International, Inc. | Endothelial cell production by programming |
EP3366327B1 (en) | 2010-07-09 | 2022-09-21 | GID BIO, Inc. | Apparatus and methods relating to collecting and processing human biological material containing adipose |
US9206387B2 (en) | 2010-07-09 | 2015-12-08 | The Gid Group, Inc. | Method and apparatus for processing adipose tissue |
US9296984B2 (en) | 2010-07-09 | 2016-03-29 | The Gid Group, Inc. | Tissue processing apparatus and method for processing adipose tissue |
WO2014039697A1 (en) | 2012-09-06 | 2014-03-13 | The Gid Group, Inc. | Tissue processing apparatus and method for processing adipose tissue |
WO2013106655A1 (en) | 2012-01-11 | 2013-07-18 | The Gid Group, Inc. | Method for processing adipose tissue and processing apparatus |
ES2666746T3 (en) | 2010-07-13 | 2018-05-07 | Anthrogenesis Corporation | Methods to generate natural cytolytic lymphocytes |
JP2013536693A (en) * | 2010-09-01 | 2013-09-26 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Cell culture screening for drugs that control adipogenesis and myofibroblast differentiation |
US9725689B2 (en) | 2010-10-08 | 2017-08-08 | Terumo Bct, Inc. | Configurable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system |
WO2012092049A2 (en) | 2010-12-29 | 2012-07-05 | Ethicon Endo-Surgery, Inc. | Brown adipocyte modification |
US8969315B2 (en) | 2010-12-31 | 2015-03-03 | Anthrogenesis Corporation | Enhancement of placental stem cell potency using modulatory RNA molecules |
JP6012629B2 (en) | 2011-01-25 | 2016-10-25 | ユニヴェルシテ カソリック ド ルーヴァンUniversite Catholique De Louvain | Compositions and methods for cell transplantation |
US9574179B2 (en) | 2011-02-08 | 2017-02-21 | Cellular Dynamics International, Inc. | Hematopoietic precursor cell production by programming |
PL2714059T3 (en) | 2011-06-01 | 2019-04-30 | Celularity Inc | Treatment of pain using placental stem cells |
PL2718416T3 (en) | 2011-06-06 | 2020-05-18 | ReGenesys BVBA | Expansion of stem cells in hollow fiber bioreactors |
WO2013010045A1 (en) | 2011-07-12 | 2013-01-17 | Biotime Inc. | Novel methods and formulations for orthopedic cell therapy |
WO2013055476A1 (en) | 2011-09-09 | 2013-04-18 | Anthrogenesis Corporation | Treatment of amyotrophic lateral sclerosis using placental stem cells |
CN103857788A (en) | 2011-10-11 | 2014-06-11 | 骨治疗公司 | Uses of growth and differentiation factor 8 (gdf-8) |
WO2013082106A1 (en) | 2011-12-02 | 2013-06-06 | The General Hospital Corporation | Differentiation into brown adipocytes |
US9775890B2 (en) | 2012-01-25 | 2017-10-03 | Université Catholique de Louvain | Factor Xa inhibitor used with liver-derived progenitor cells |
EP2832850B1 (en) | 2012-03-29 | 2017-09-06 | JCR Pharmaceuticals Co., Ltd. | Method for producing pluripotent stem cells derived from dental pulp |
US11458166B2 (en) | 2012-09-26 | 2022-10-04 | Bone Therapeutics S.A | Formulations involving solvent/detergent-treated plasma (S/D plasma) and uses thereof |
WO2014082042A2 (en) | 2012-11-25 | 2014-05-30 | The Regents Of The University Of California | Peptides that stimulate subcutaneous adipogenesis |
US9763983B2 (en) | 2013-02-05 | 2017-09-19 | Anthrogenesis Corporation | Natural killer cells from placenta |
US20140242595A1 (en) | 2013-02-22 | 2014-08-28 | Cellular Dynamics International, Inc. | Hepatocyte production via forward programming by combined genetic and chemical engineering |
CA2899713C (en) | 2013-03-15 | 2022-07-19 | Allosource | Cell repopulated collagen matrix for soft tissue repair and regeneration |
JP6602288B2 (en) | 2013-04-03 | 2019-11-06 | フジフィルム セルラー ダイナミクス,インコーポレイテッド | Methods and compositions for culturing endoderm progenitor cells in suspension |
ES2827250T3 (en) | 2013-04-12 | 2021-05-20 | Houston Methodist Hospital | Improvement of organs for transplantation |
DK2992088T3 (en) | 2013-04-30 | 2019-11-11 | Univ Leuven Kath | CELL THERAPY FOR MYELODYSPLASTIC SYNDROMES |
WO2015035221A1 (en) | 2013-09-05 | 2015-03-12 | The Gid Group, Inc. | Tissue processing apparatus and method for processing adipose tissue |
WO2015073913A1 (en) | 2013-11-16 | 2015-05-21 | Terumo Bct, Inc. | Expanding cells in a bioreactor |
WO2015148704A1 (en) | 2014-03-25 | 2015-10-01 | Terumo Bct, Inc. | Passive replacement of media |
US20170107486A1 (en) | 2014-04-21 | 2017-04-20 | Cellular Dynamics International, Inc. | Hepatocyte production via forward programming by combined genetic and chemical engineering |
US10844102B2 (en) | 2014-05-28 | 2020-11-24 | The Regents Of The University Of California | Peptides, compositions, and methods for stimulating subcutaneous adipogenesis |
EP3677288A1 (en) | 2014-09-19 | 2020-07-08 | Osiris Therapeutics, Inc. | Bone repair product and methods of use thereof |
US20170296589A1 (en) | 2014-09-23 | 2017-10-19 | Case Western Reserve University | Compositions and methods for treating lung remodeling diseases |
CN106715676A (en) | 2014-09-26 | 2017-05-24 | 泰尔茂比司特公司 | Scheduled feed |
EP3189828B1 (en) | 2014-11-07 | 2020-07-29 | Exostemtech Co., Ltd. | Composition for differentiation induction of adipocyte containing stem cell-derived exosome, regeneration of adipose tissue, and skin whitening or wrinkle improvement |
KR101629151B1 (en) * | 2014-11-07 | 2016-06-10 | 한양대학교 에리카산학협력단 | Composition including stem cell-derived exosome for inducing adipogenic differentiation and adipose tissue regeneration |
US10092738B2 (en) | 2014-12-29 | 2018-10-09 | Ethicon Llc | Methods and devices for inhibiting nerves when activating brown adipose tissue |
US10080884B2 (en) | 2014-12-29 | 2018-09-25 | Ethicon Llc | Methods and devices for activating brown adipose tissue using electrical energy |
WO2016170112A1 (en) | 2015-04-23 | 2016-10-27 | Bone Therapeutics S.A. | In vitro preservation of therapeutic cells |
WO2017004592A1 (en) | 2015-07-02 | 2017-01-05 | Terumo Bct, Inc. | Cell growth with mechanical stimuli |
WO2017210537A1 (en) | 2016-06-02 | 2017-12-07 | The Cleveland Clinic Foundation | Complement inhibition for improving cell viability |
US11685883B2 (en) | 2016-06-07 | 2023-06-27 | Terumo Bct, Inc. | Methods and systems for coating a cell growth surface |
US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
AU2017319140B2 (en) | 2016-08-30 | 2022-11-17 | Lifecell Corporation | Systems and methods for medical device control |
USD851777S1 (en) | 2017-01-30 | 2019-06-18 | Lifecell Corporation | Canister-type device for tissue processing |
US11702634B2 (en) | 2017-03-31 | 2023-07-18 | Terumo Bct, Inc. | Expanding cells in a bioreactor |
US11624046B2 (en) | 2017-03-31 | 2023-04-11 | Terumo Bct, Inc. | Cell expansion |
WO2019018002A1 (en) | 2017-07-18 | 2019-01-24 | The Gid Group, Inc. | Adipose tissue digestion system and tissue processing method |
AU2018351804B2 (en) | 2017-10-20 | 2020-07-09 | Bone Therapeutics Sa | Methods for differentiating mesenchymal stem cells |
US11530387B2 (en) | 2017-11-16 | 2022-12-20 | Nissan Chemical Corporation | Method for inducing differentiation into and producing beige and white adipocytes |
JPWO2020027163A1 (en) | 2018-07-31 | 2021-09-24 | Jcrファーマ株式会社 | Method for producing dental pulp-derived cells |
BE1026595B9 (en) | 2018-09-25 | 2020-11-03 | Bone Therapeutics Sa | METHODS OF DIFFERENTIATING MESENCHYMATIC STEM CELLS |
AU2019349633A1 (en) | 2018-09-25 | 2021-05-27 | Bone Therapeutics Sa | Methods and uses for determining osteogenic potential of in vitro differentiated cells |
AR118008A1 (en) | 2019-02-07 | 2021-09-08 | Vitricell Sa | COMPOSITIONS FOR CRYOPRESERVATION OF A BIOLOGICAL MATERIAL |
CN113825498A (en) | 2019-05-13 | 2021-12-21 | 骨治疗公司 | Improved lyophilized formulations comprising hyaluronic acid and plasma proteins and uses thereof |
EP3994245A1 (en) | 2019-07-05 | 2022-05-11 | Case Western Reserve University | Priming media and methods for stem cell culture and therapy |
WO2021153719A1 (en) | 2020-01-30 | 2021-08-05 | Jcrファーマ株式会社 | Medicinal composition comprising dental pulp-derived cells |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5486359A (en) * | 1990-11-16 | 1996-01-23 | Osiris Therapeutics, Inc. | Human mesenchymal stem cells |
US5827740A (en) * | 1996-07-30 | 1998-10-27 | Osiris Therapeutics, Inc. | Adipogenic differentiation of human mesenchymal stem cells |
-
1996
- 1996-07-30 US US08/700,753 patent/US5827740A/en not_active Expired - Lifetime
-
1997
- 1997-07-21 DK DK97934171T patent/DK0954565T3/en active
- 1997-07-21 DE DE69736814T patent/DE69736814T2/en not_active Expired - Lifetime
- 1997-07-21 EP EP06002113A patent/EP1659172A1/en not_active Ceased
- 1997-07-21 PT PT97934171T patent/PT954565E/en unknown
- 1997-07-21 ES ES97934171T patent/ES2274547T3/en not_active Expired - Lifetime
- 1997-07-21 AU AU37290/97A patent/AU3729097A/en not_active Abandoned
- 1997-07-21 WO PCT/US1997/012356 patent/WO1998004682A1/en active IP Right Grant
- 1997-07-21 CA CA2262014A patent/CA2262014C/en not_active Expired - Fee Related
- 1997-07-21 EP EP97934171A patent/EP0954565B1/en not_active Expired - Lifetime
- 1997-07-21 JP JP50885998A patent/JP2001523084A/en active Pending
- 1997-07-21 AT AT97934171T patent/ATE342349T1/en not_active IP Right Cessation
-
1998
- 1998-10-26 US US09/246,003 patent/US6322784B1/en not_active Expired - Lifetime
-
2000
- 2000-03-28 US US09/537,003 patent/US6709864B1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
ATE342349T1 (en) | 2006-11-15 |
US6709864B1 (en) | 2004-03-23 |
US6322784B1 (en) | 2001-11-27 |
AU3729097A (en) | 1998-02-20 |
DE69736814T2 (en) | 2007-08-16 |
DE69736814D1 (en) | 2006-11-23 |
EP0954565A1 (en) | 1999-11-10 |
CA2262014A1 (en) | 1998-02-05 |
EP1659172A1 (en) | 2006-05-24 |
DK0954565T3 (en) | 2007-02-05 |
WO1998004682A1 (en) | 1998-02-05 |
EP0954565B1 (en) | 2006-10-11 |
EP0954565A4 (en) | 2002-09-18 |
ES2274547T3 (en) | 2007-05-16 |
JP2001523084A (en) | 2001-11-20 |
PT954565E (en) | 2007-01-31 |
US5827740A (en) | 1998-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2262014C (en) | Adipogenic differentiation of human mesenchymal stem cells | |
Grigoriadis et al. | Differentiation of muscle, fat, cartilage, and bone from progenitor cells present in a bone-derived clonal cell population: effect of dexamethasone. | |
Poliard et al. | Controlled conversion of an immortalized mesodermal progenitor cell towards osteogenic, chondrogenic, or adipogenic pathways. | |
TWI278518B (en) | Methods and compositions for the differentiation of human preadipocytes into adipocytes | |
Avram et al. | Subcutaneous fat in normal and diseased states: 3. Adipogenesis: from stem cell to fat cell | |
US5942225A (en) | Lineage-directed induction of human mesenchymal stem cell differentiation | |
US7341719B1 (en) | Myoblast therapy for cosmetic treatment | |
US20100129330A1 (en) | Adipocytic differentiated adipose derived adult stem cells and uses thereof | |
Niemelä et al. | Fat tissue: views on reconstruction and exploitation | |
Van Robin et al. | Complete differentiation in vivo of implanted cultured adipocyte precursors from adult rats | |
WO2000027996A1 (en) | Serum free medium for chondrocyte-like cells | |
Aikawa et al. | Establishment of bone morphogenetic protein 2 responsive chondrogenic cell line | |
AU765354B2 (en) | Adipogenic differentiation of human mesenchymal stem cells | |
AU2003234740B2 (en) | Adipogenic Differentiation of Human Mesenchymal Stem Cells | |
Ishizeki et al. | Meckel's cartilage chondrocytes in organ culture synthesize bone-type proteins accompanying osteocytic phenotype expression | |
Hung et al. | Alpha-smooth muscle actin expression and structure integrity in chondrogenesis of human mesenchymal stem cells | |
Wang et al. | Peroxisome proliferator-activated receptor-γ promotes adipogenic changes in growth plate chondrocytes in vitro | |
Zhou et al. | A novel experimental study on establish a myoblasts differentiated cell sheet using induced adipose-derived stem cell technology | |
Nagata et al. | Increased peptidylarginine deiminase expression during induction of prolactin biosynthesis in a growth‐hormone‐producing rat pituitary cell line, MtT/S | |
US20030103947A1 (en) | In vitro engineered cartilage constructs produced by coating biodegradable polymer with human mesenchymal stem cells | |
Shumakov et al. | Differentiation of bone marrow stromal stem cells into cardiomyocyte-like cells in different mammalian species | |
Price et al. | O8. Type X collagen and aggrecan expression in deer antler an in situ hybridization and immunocytochemical study | |
CA2809164C (en) | Postnatal stem cells and uses thereof | |
Roodman | Model systems of osteoclast differentiation | |
Chen et al. | In vitro osteoblast characteristics and in vivo bone formation of adult human and rabbit adipose-derived cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |